```
=> d his ful

     (FILE 'REGISTRY' ENTERED AT 09:45:52 ON 30 JAN 2006)
                DEL HIS Y
                ACT MITCH/A
               ---------
L1              STR
L2            37 SEA FAM FUL L1
               ---------
L3             2 SEA ABB=ON  PLU=ON  L2 AND CA/ELS
L4             1 SEA ABB=ON  PLU=ON  L2 AND MG/ELS
L5             1 SEA ABB=ON  PLU=ON  L2 AND 625-08-1

     FILE 'CAPLUS' ENTERED AT 09:49:28 ON 30 JAN 2006
L6            17 SEA ABB=ON  PLU=ON  L3 OR L4
L7             4 SEA ABB=ON  PLU=ON  L6 AND (PHARMACEUT?/OBI OR 63/SX,SC)
                D SCAN
L8             2 SEA ABB=ON  PLU=ON  L6 AND PARENTER?/BI
L9        145270 SEA ABB=ON  PLU=ON  DRUG DELIVER?/OBI
L10            4 SEA ABB=ON  PLU=ON  L9 AND L6
L11            6 SEA ABB=ON  PLU=ON  L7 OR L8 OR L10

     FILE 'REGISTRY' ENTERED AT 09:53:11 ON 30 JAN 2006
                E CALCIUM/CN
L12            1 SEA ABB=ON  PLU=ON  CALCIUM/CN
                E CALCIUM ION/CN
L13            1 SEA ABB=ON  PLU=ON  "CALCIUM ION"/CN
                E MAGNESIUM/CN
L14            1 SEA ABB=ON  PLU=ON  MAGNESIUM/CN
                E MAGNESIUM ION/CN
L15            1 SEA ABB=ON  PLU=ON  "MAGNESIUM ION"/CN

     FILE 'CAPLUS' ENTERED AT 09:53:49 ON 30 JAN 2006

L16       374965 SEA ABB=ON  PLU=ON  L12 OR L13
L17       218071 SEA ABB=ON  PLU=ON  L14 OR L15
L18          317 SEA ABB=ON  PLU=ON  L5
L19           12 SEA ABB=ON  PLU=ON  L18 AND L16
L20           11 SEA ABB=ON  PLU=ON  L18 AND L17
L21           14 SEA ABB=ON  PLU=ON  (L19 OR L20)
L22           10 SEA ABB=ON  PLU=ON  L21 AND ((PARENTER? OR PHARMACEU?)/BI OR
                L9 OR 63/SX,SC)
L23           15 SEA ABB=ON  PLU=ON  L22 OR L11
                D TI 1-10
L24         4374 SEA ABB=ON  PLU=ON  (HYPOCALCEMIA OR HYPOMAGNESIA OR HYPERKALEM
                IA)/BI
L25            1 SEA ABB=ON  PLU=ON  L24 AND L18
L26            1 SEA ABB=ON  PLU=ON  L24 AND L6
L27            1 SEA ABB=ON  PLU=ON  L25 OR L26
                D SCAN
L28           15 SEA ABB=ON  PLU=ON  L27 OR L23
L29           36 SEA ABB=ON  PLU=ON  DOBBINS T?/AU
L30          353 SEA ABB=ON  PLU=ON  WILEY D?/AU
L31         3592 SEA ABB=ON  PLU=ON  DAVIS M?/AU
L32         3974 SEA ABB=ON  PLU=ON  (L29 OR L30 OR L31)
L33          347 SEA ABB=ON  PLU=ON  L2
L34            3 SEA ABB=ON  PLU=ON  L33 AND L32
                D SCAN
L35           71 SEA ABB=ON  PLU=ON  L33 (L) (FFD OR THU OR USES)/RL
L36           41 SEA ABB=ON  PLU=ON  L35 AND (63 OR 18 OR 17)/SC,SX
```

L37	21	SEA ABB=ON	PLU=ON	L35 AND (63 OR 17)/SC,SX
L38	10	SEA ABB=ON	PLU=ON	L37 NOT L28
		D SCAN TI		
L39	0	SEA ABB=ON	PLU=ON	L34 NOT L28

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:02:50 ON 30 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JAN 2006  HIGHEST RN 872967-60-7
DICTIONARY FILE UPDATES:  29 JAN 2006  HIGHEST RN 872967-60-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que l2
L1                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L2            37 SEA FILE=REGISTRY FAM FUL L1
```

```
=> d que l2
L1                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L2            37 SEA FILE=REGISTRY FAM FUL L1


=> d que nos l3;d l3 1-2
L1                STR
L2            37 SEA FILE=REGISTRY FAM FUL L1
L3             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND CA/ELS



L3   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   176389-82-5  REGISTRY
ED   Entered STN:  17 May 1996
CN   Butanoic acid, 3-hydroxy-3-methyl-, calcium salt (1:1) (9CI)  (CA INDEX
     NAME)
MF   C5 H10 O3 . Ca
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
CRN  (625-08-1)
```




```
             4 REFERENCES IN FILE CA (1907 TO DATE)
             4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   135236-72-5  REGISTRY
```

ED Entered STN: 02 Aug 1991
CN Butanoic acid, 3-hydroxy-3-methyl-, calcium salt (2:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Calcium β-hydroxy-β-methylbutyrate
MF **C5 H10 O3 . 1/2 Ca**
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPATFULL
CRN (625-08-1)



● 1/2 Ca

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> d que nos l4;d l4
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND MG/ELS
```

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 786710-98-3 REGISTRY
ED Entered STN: 23 Nov 2004
CN Butanoic acid, 3-hydroxy-3-methyl-, magnesium salt (1:1) (9CI) (CA INDEX NAME)
MF **C5 H10 O3 . Mg**
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (625-08-1)



● Mg

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> d que nos l5; d l5
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L5            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND 625-08-1
```

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN **625-08-1** REGISTRY
ED Entered STN: 16 Nov 1984
CN Butanoic acid, 3-hydroxy-3-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butyric acid, 3-hydroxy-3-methyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN β-Hydroxy-β-methylbutyric acid
CN β-Hydroxyisovaleric acid
CN 3-Hydroxy-3-methylbutanoic acid
CN 3-Hydroxy-3-methylbutyric acid
CN 3-Hydroxyisovaleric acid
FS 3D CONCORD
MF C5 H10 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE, IPA, MEDLINE, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

317 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
317 REFERENCES IN FILE CAPLUS (1907 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> d que l12;d l12
L12           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  CALCIUM/CN
```

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7440-70-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN **Calcium (8CI, 9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Atomic calcium

CN Blood-coagulation factor IV
CN Calcium atom
CN Calcium element
CN Praval
DR 8047-59-4
MF Ca
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Ca

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

365336 REFERENCES IN FILE CA (1907 TO DATE)
8501 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
365675 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d que l13;d l13
L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CALCIUM ION"/CN

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 14127-61-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Calcium, ion (Ca2+) (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ca2+
CN Calcium (II) ion
CN Calcium cation
CN Calcium dication
CN **Calcium ion**
CN Calcium ion(2+)
CN Calcium(2+)
CN Calcium(2+) ion
MF Ca
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, NIOSHTIC, PIRA, PROMT, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

Ca^{2+}

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10263 REFERENCES IN FILE CA (1907 TO DATE)
177 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10286 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d que l14;d l14
L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON MAGNESIUM/CN

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 7439-95-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN **Magnesium (8CI, 9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Ecka Granules PK 31
CN Ecka Granules PK 51
CN Magnesium element
CN PK 31
CN PK 51
CN Rieke's active magnesium
DR 14147-08-1, 67208-78-0, 199281-20-4, 298688-48-9
MF Mg
CI COM
LC STN Files: ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS*, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Mg

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

212189 REFERENCES IN FILE CA (1907 TO DATE)
8119 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
212373 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d que l15;d l15
L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "MAGNESIUM ION"/CN

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 22537-22-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Magnesium, ion (Mg2+) (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Magnesium (Mg2+)
CN Magnesium cation
CN Magnesium cation(2+)
CN Magnesium dication
CN **Magnesium ion**
CN Magnesium ion(2+)
CN Magnesium(2+)
CN Magnesium(II)
CN Magnesium(II) ion
CN Mg2+
MF Mg
CI COM
LC STN Files: AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, DDFU, DETHERM*, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, NIOSHTIC, PIRA, PROMT, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

Mg^{2+}

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6166 REFERENCES IN FILE CA (1907 TO DATE)
158 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6175 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus
FILE 'CAPLUS' ENTERED AT 10:04:31 ON 30 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jan 2006 VOL 144 ISS 6
FILE LAST UPDATED: 29 Jan 2006 (20060129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

```
=> d que nos l28
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L3            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND CA/ELS
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND MG/ELS
L5            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND 625-08-1
L6           17 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 OR L4
L7            4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6 AND (PHARMACEUT?/OBI OR
                63/SX,SC)
L8            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6 AND PARENTER?/BI
L9       145270 SEA FILE=CAPLUS ABB=ON  PLU=ON  DRUG DELIVER?/OBI
L10           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 AND L6
L11           6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 OR L8 OR L10
L12           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  CALCIUM/CN
L13           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CALCIUM ION"/CN
L14           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  MAGNESIUM/CN
L15           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "MAGNESIUM ION"/CN
L16      374965 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 OR L13
L17      218071 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 OR L15
L18         317 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5
L19          12 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND L16
L20          11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND L17
L21          14 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L19 OR L20)
L22          10 SEA FILE=CAPLUS ABB=ON  PLU=ON  L21 AND ((PARENTER? OR
                PHARMACEU?)/BI OR L9 OR 63/SX,SC)
L23          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L22 OR L11
L24        4374 SEA FILE=CAPLUS ABB=ON  PLU=ON  (HYPOCALCEMIA OR HYPOMAGNESIA
                OR HYPERKALEMIA)/BI
L25           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L18
L26           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L6
L27           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L25 OR L26
L28          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L27 OR L23


=> d que nos l38
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L3            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND CA/ELS
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND MG/ELS
L5            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND 625-08-1
L6           17 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 OR L4
L7            4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6 AND (PHARMACEUT?/OBI OR
                63/SX,SC)
L8            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6 AND PARENTER?/BI
L9       145270 SEA FILE=CAPLUS ABB=ON  PLU=ON  DRUG DELIVER?/OBI
L10           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 AND L6
L11           6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 OR L8 OR L10
L12           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  CALCIUM/CN
L13           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CALCIUM ION"/CN
L14           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  MAGNESIUM/CN
L15           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "MAGNESIUM ION"/CN
L16      374965 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 OR L13
L17      218071 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 OR L15
L18         317 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5
L19          12 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND L16
L20          11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND L17
L21          14 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L19 OR L20)
L22          10 SEA FILE=CAPLUS ABB=ON  PLU=ON  L21 AND ((PARENTER? OR
                PHARMACEU?)/BI OR L9 OR 63/SX,SC)
```

```
L23          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L22 OR L11
L24        4374 SEA FILE=CAPLUS ABB=ON  PLU=ON  (HYPOCALCEMIA OR HYPOMAGNESIA
                OR HYPERKALEMIA)/BI
L25           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L18
L26           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L6
L27           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L25 OR L26
L28          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L27 OR L23
L33         347 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L35          71 SEA FILE=CAPLUS ABB=ON  PLU=ON  L33 (L) (FFD OR THU OR
                USES)/RL
L37          21 SEA FILE=CAPLUS ABB=ON  PLU=ON  L35 AND (63 OR 17)/SC,SX
L38          10 SEA FILE=CAPLUS ABB=ON  PLU=ON  L37 NOT L28


=> d que nos l39
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L3            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND CA/ELS
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND MG/ELS
L5            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 AND 625-08-1
L6           17 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3 OR L4
L7            4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6 AND (PHARMACEUT?/OBI OR
                63/SX,SC)
L8            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L6 AND PARENTER?/BI
L9       145270 SEA FILE=CAPLUS ABB=ON  PLU=ON  DRUG DELIVER?/OBI
L10           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 AND L6
L11           6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 OR L8 OR L10
L12           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  CALCIUM/CN
L13           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CALCIUM ION"/CN
L14           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  MAGNESIUM/CN
L15           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "MAGNESIUM ION"/CN
L16      374965 SEA FILE=CAPLUS ABB=ON  PLU=ON  L12 OR L13
L17      218071 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 OR L15
L18         317 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5
L19          12 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND L16
L20          11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 AND L17
L21          14 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L19 OR L20)
L22          10 SEA FILE=CAPLUS ABB=ON  PLU=ON  L21 AND ((PARENTER? OR
                PHARMACEU?)/BI OR L9 OR 63/SX,SC)
L23          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L22 OR L11
L24        4374 SEA FILE=CAPLUS ABB=ON  PLU=ON  (HYPOCALCEMIA OR HYPOMAGNESIA
                OR HYPERKALEMIA)/BI
L25           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L18
L26           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L6
L27           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L25 OR L26
L28          15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L27 OR L23
L29          36 SEA FILE=CAPLUS ABB=ON  PLU=ON  DOBBINS T?/AU
L30         353 SEA FILE=CAPLUS ABB=ON  PLU=ON  WILEY D?/AU
L31        3592 SEA FILE=CAPLUS ABB=ON  PLU=ON  DAVIS M?/AU
L32        3974 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L29 OR L30 OR L31)
L33         347 SEA FILE=CAPLUS ABB=ON  PLU=ON  L2
L34           3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L33 AND L32
L39           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L34 NOT L28

=> d l28 .ca 1-15;d .ca l38 1-10

L28  ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1050884  CAPLUS
DOCUMENT NUMBER:          143:299157
TITLE:                    Hydroxy-beta-methylbutyric acid for inflammatory
```

diseases, cancer, and involuntary weight loss
INVENTOR(S): Baxter, Jeffrey H.; Mukerji, Pradip; Voss, Anne C.; Tisdale, Michael J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005215640	A1	20050929	US 2004-810762	20040326
WO 2005102301	A2	20051103	WO 2005-US7951	20050314

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-810762 A 20040326
ED Entered STN: 30 Sep 2005
AB The invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixts. thereof. HMB may be added to nutritional supplements and food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
IC ICM A61K031-202
INCL 514560000
CC 1-12 (Pharmacology)
Section cross-reference(s): 18
IT AIDS (disease)
Animal
Anti-AIDS agents
Anti-inflammatory agents
Antiarthritics
Antitumor agents
Arthritis
Cachexia
Combination chemotherapy
Drug delivery systems
Human
Inflammation
Kidney, disease
Liver, disease
Neoplasm
Protein degradation
(hydroxy-beta-methylbutyric acid for inflammatory diseases, cancer, and involuntary weight loss)
IT 10417-94-4, Eicosapentaenoic acid **176389-82-5**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy-beta-methylbutyric acid for inflammatory diseases, cancer, and involuntary weight loss)

IT 541-15-1, L-Carnitine 625-08-1D, alkali metal, alkali earth metal salt 625-08-1D, chromium salts 1823-52-5 6217-54-5, Docosahexaenoic acid 155206-13-6 155206-14-7 **786710-98-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy-beta-methylbutyric acid for inflammatory diseases, cancer, and involuntary weight loss)

L28 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:904349 CAPLUS
DOCUMENT NUMBER: 143:248278
TITLE: Preparation of sulfonylpyrrolidines as modulators of androgen receptor
INVENTOR(S): Hamann, Lawrence G.; Bi, Yingzhi; Manfredi, Mark C.; Nirschl, Alexandra A.; Sutton, James C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187267	A1	20050825	US 2005-48439	20050201
PRIORITY APPLN. INFO.:			US 2004-541869P P	20040204

OTHER SOURCE(S): MARPAT 143:248278
ED Entered STN: 26 Aug 2005
GI



I



II



III

AB Title compds. I or II [R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, SR6, etc.; R3 and R4 independently = H, (un)substituted alkynyl, cycloalkyl, etc.; R5 = H, (un)substituted aryl, arylalkyl, etc.; R6 = H, CHF2, CF3, etc.; X = (CH2)n; G = (un)substituted aryl, heterocycle or heteroaryl; Z = O or NR7; R7 = H, (un)substituted alkyl, alkenyl, etc.; n and m independently = 1-2] and their **pharmaceutically** acceptable salts, are prepared and disclosed as modulators of androgen receptor. Thus, e.g., III was prepared by hydrolysis of (2S,3R)-1-(3-chloro-4-cyano-2-methyl-phenylsulfamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid Me ester (preparation given) followed by cyclization. The activity of I was evaluated in transactivation assays of a transfected reporter construct and using the endogenous androgen receptor of the host cells (no data). I as modulator of androgen receptor should prove useful in the treatment of neoplasm, Alzheimer's disease and obesity. **Pharmaceutical** compns. comprising I are disclosed.

IC ICM A61K031-433
ICS A61K031-4015; C07D498-04

INCL 514362000; 514423000; 548537000; 548126000

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, **63**

IT Natural products, **pharmaceutical**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis, claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

IT 50-02-2 50-07-7 50-18-0 50-44-2 50-76-0, Actinomycin D 50-78-2 50-81-7, L-Ascorbic acid, biological studies 51-21-8 51-64-9 52-01-7 52-24-4 52-53-9 53-03-2 53-19-0 53-43-0 53-86-1 54-31-9 55-86-7 55-98-1 56-03-1, Imidodicarbonimidic diamide 56-53-1 57-22-7 57-47-6 57-83-0, Pregn-4-ene-3,20-dione, biological studies 58-22-0 58-32-2 58-54-8 58-55-9, biological studies 58-93-5 58-94-6 59-05-2 59-30-3, biological studies 60-27-5 61-90-5, L-Leucine, biological studies 68-19-9, Vitamin B12 68-26-8, Retinol 71-58-9 73-48-3 76-60-8 77-36-1 91-33-8 122-09-8 127-07-1 133-67-5 135-07-9 135-09-1 147-94-4 148-56-1 148-82-3 151-56-4, Aziridine, biological studies 154-42-7 154-93-8 155-97-5 302-79-4, Retinoic acid 303-98-0 305-03-3 321-64-2 346-18-9 378-44-9 396-01-0 439-14-5 541-15-1 595-33-5 604-75-1 **625-08-1** 630-60-4 645-05-6 657-24-9 671-16-9 797-63-7 846-49-1 865-21-4, Vincaleukoblastine 1200-22-2 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1605-68-1 2030-63-9 2295-31-0, 2,4-Thiazolidinedione 2609-46-3 2998-57-4 3056-17-5 3778-73-2 4205-90-7 4291-63-8 4342-03-4 4375-07-9 5630-53-5 **7439-95-4**, Magnesium, biological studies 7440-09-7, Potassium, biological studies 7440-47-3, Chromium, biological studies 7440-66-6, Zinc, biological studies **7440-70-2**, Calcium, biological studies 7481-89-2 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9002-64-6, Parathormone 9002-71-5, Thyrotropin 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9015-68-3, Asparaginase 9041-93-4 10238-21-8 10246-75-0 10540-29-1 11056-06-7, Bleomycin 13010-20-3 13010-47-4 13311-84-7 13909-09-6 14769-73-4 14838-15-4 15056-34-5, 1-Triazene 15663-27-1 15687-27-1 16984-48-8, Fluoride, biological studies 18378-89-7 18883-66-4 20830-81-3 21679-14-1 21829-25-4 22204-53-1 22232-71-9 24305-27-9 25316-40-9 26027-38-3 26538-44-3 28395-03-1 29094-61-9 29767-20-2 30516-87-1 33069-62-4 33419-42-0 35212-22-7 36085-73-1 36322-90-4 36505-84-7 38304-91-5 40180-04-9 41575-94-4 42399-41-7 51333-22-3 52205-73-9 53714-56-0 53910-25-1 54870-28-9 54910-89-3 55142-85-3 55294-15-0 56180-94-0 57982-77-1 58095-31-1 58957-92-9

59729-33-8 59865-13-3, Cyclosporin A 61869-08-7 62571-86-2
66376-36-1 67763-96-6, Insulin-like growth factor I 67763-97-7,
Insulin-like growth factor II 69655-05-6 73963-72-1 75330-75-5
75425-66-0 75847-73-3 76547-98-3 79517-01-4 79617-96-2
79902-63-9 81093-37-0 81872-10-8 82924-03-6 83366-66-9
83435-66-9 84449-90-1 85441-61-8 87333-19-5 87616-84-0
88150-42-9 88768-40-5 93479-97-1 96829-58-2 97240-79-4
97322-87-7 98048-97-6 98319-26-7 100286-90-6 104987-11-3
105462-24-6 106650-56-0 107724-20-9 110942-02-4 111025-46-8
111223-26-8 113665-84-2 114798-26-4 114977-28-5 116644-53-2
116680-01-4 117091-64-2 120014-06-4 121181-53-1 122111-03-9
122320-73-4 123441-03-2 123774-72-1 123948-87-8 125317-39-7
127779-20-8 129318-43-0 134523-00-5 134678-17-4 135062-02-1
137109-78-5 137862-53-4 138402-11-6 139755-83-2 141626-36-0
141750-63-2 143443-90-7 143653-53-6 144494-65-5 147030-48-6
147191-91-1 147511-69-1 149845-06-7 150322-43-3 155213-67-5
157810-81-6 158861-67-7 159183-92-3 159752-10-0 160135-92-2
162011-90-7 164301-51-3 167305-00-2 169590-42-5 170277-31-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

L28 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:902874 CAPLUS
DOCUMENT NUMBER: 143:248277
TITLE: Preparation of sulfonylpyrrolidines as modulators of androgen receptor
INVENTOR(S): Hamann, Lawrence H.; Bi, Yingzhi; Manfredi, Mark C.; Nirschl, Alexandra A.; Sutton, James C.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077925	A1	20050825	WO 2005-US2834	20050202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-541869P P 20040204
OTHER SOURCE(S): MARPAT 143:248277
ED Entered STN: 26 Aug 2005
GI



I



II



III

AB Title compds. I or II [R1 = H, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, SR6, etc.; R3 and R4 independently = H, (un)substituted alkynyl, cycloalkyl, etc.; R5 = H, (un)substituted aryl, arylalkyl, etc.; R6 = H, CHF2, CF3, etc.; X = (CH2)n; G = (un)substituted aryl, heterocycle or heteroaryl; Z = O or NR7; R7 = H, (un)substituted alkyl, alkenyl, etc.; n and m independently = 1-2] and their **pharmaceutically** acceptable salts, are prepared and disclosed as modulators of androgen receptor. Thus, e.g., III was prepared by hydrolysis of (2S,3R)-1-(3-chloro-4-cyano-2-methyl-phenylsulfamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid Me ester (preparation given) followed by cyclization. The activity of I was evaluated in transactivation assays of a transfected reporter construct and using the endogenous androgen receptor of the host cells (no data). I as modulator of androgen receptor should prove useful in the treatment of neoplasm, Alzheimer's disease and obesity. **Pharmaceutical** compns. comprising I are disclosed.

IC ICM C07D285-06
ICS A61K031-433

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, **63**

IT Natural products, **pharmaceutical**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis, claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

IT 50-02-2, Dexamethasone 50-07-7, Mitomycin 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil 51-64-9, Dexamphetamine 52-01-7, Spironolactone 52-24-4, Thiotepa 52-53-9, Verapamil 53-03-2, Prednisone 53-19-0, Mitotane 53-43-0, Dehydroepiandrosterone 53-86-1, Indomethacin 54-31-9, Furosemide 55-86-7, Nitrogen mustard 55-98-1, Busulfan 56-03-1, Biguanide 56-53-1 57-22-7, Vincristine 57-47-6, Physostigmine 57-83-0, Progestin, biological studies 58-22-0, Testosterone 58-32-2, Dipyridamole 58-54-8 58-55-9, Theophylline, biological studies

58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, biological studies 60-27-5, Creatinine 61-90-5, Leucine, biological studies 68-19-9, Vitamin B12 68-26-8, Vitamin A 71-58-9, Medroxyprogesterone acetate 73-48-3, Bendroflumethiazide 76-60-8, BCG 77-36-1, Chlorthalidone 91-33-8, Benzthiazide 122-09-8, Phentermine 127-07-1, Hydroxyurea 133-67-5, Trichloromethiazide 135-07-9 135-09-1, Hydroflumethiazide 147-94-4, Cytarabine 148-56-1, Flumethiazide 148-82-3, Melphalan 151-56-4, Ethylenimine, biological studies 154-42-7, Thioguanine 154-93-8, Carmustin 155-97-5, Pyridostigmine 302-79-4, Retinoic acid 303-98-0, Coenzyme Q-10 305-03-3, Chlorambucil 321-64-2, Tacrine 346-18-9, Polythiazide 378-44-9, BetaMethasone 396-01-0, Triamterene 439-14-5, Diazepam 541-15-1, Carnitine 595-33-5, Megestrol acetate 604-75-1, Oxazepam **625-08-1**, β-Hydroxy-β-methylbutyric acid 630-60-4, Ouabain 645-05-6, Hexamethylmelamine 657-24-9, Metformin 671-16-9, Procarbazine 797-63-7, Levonorgestrel 846-49-1, Lorazepam 865-21-4, Vinblastine 1200-22-2, Lipoic acid 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1605-68-1, Taxane 2030-63-9, Clofazimine 2295-31-0, Thiazolidinedione 2609-46-3, Amiloride 2998-57-4, Estramustine 3056-17-5, Stavudine 3778-73-2, Ifosfamide 4205-90-7, Clonidine 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4375-07-9, Epipodophyllotoxin 5630-53-5, Tibolone **7439-95-4**, Magnesium, biological studies 7440-09-7, Potassium, biological studies 7440-47-3, Chromium, biological studies 7440-66-6, Zinc, biological studies **7440-70-2**, Calcium, biological studies 7481-89-2, Zalcitabine 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9002-64-6, Parathyroid hormone 9002-71-5, Thyrotropin 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 9015-68-3, L-Asparaginase 9041-93-4, Bleomycin sulfate 10238-21-8, Glyburide 10246-75-0, Hydroxyzine pamoate 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-20-3, Nitrosourea 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 15056-34-5, Triazene 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 16984-48-8, Fluoride, biological studies 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 24305-27-9, Trh 25316-40-9, Adriamycin 26027-38-3, Nonoxynol 9 26538-44-3, Zeranol 28395-03-1, Bumetanide 29094-61-9, Glipizide 29767-20-2, Teniposide 30516-87-1, Zidovudine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 35212-22-7, Ipriflavone 36085-73-1, B-HT920 36322-90-4, Piroxicam 36505-84-7, Buspirone 38304-91-5, Minoxidil 40180-04-9, Ticrynafen 41575-94-4, Carboplatin 42399-41-7, Diltiazem 51333-22-3, Budesonide 52205-73-9, Estramustine phosphate sodium 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54870-28-9, Meglitinide 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55294-15-0, Muzolimine 56180-94-0, Acarbose 57982-77-1, Buserelin 58095-31-1, Sulbenox 58957-92-9, Idarubicin 59729-33-8, Citalopram 59865-13-3, Cyclosporin A 61869-08-7, Paroxetine 62571-86-2, Captopril 66376-36-1, Alendronate 67763-96-6, IGF-1 67763-97-7, IGF-2 69655-05-6, Didanosine 73963-72-1, Cilostazol 75330-75-5, Lovastatin 75425-66-0, Saframycins 75847-73-3, Enalapril 76547-98-3, Lisinopril 79517-01-4, Octreotide acetate 79617-96-2, Sertraline 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81872-10-8, Zofenopril 82924-03-6, Pentopril 83366-66-9, Nefazodone 83435-66-9, Delapril 84449-90-1, Raloxifene 85441-61-8, Quinapril 87333-19-5, Ramipril 87616-84-0 88150-42-9, Amlodipine 88768-40-5 93479-97-1, Glimepiride 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 98319-26-7, Finasteride 100286-90-6, Irinotecan hydrochloride 104987-11-3, FK-506 105462-24-6 106650-56-0, Sibutramine

107724-20-9, Eplerenone 110942-02-4, Aldesleukin 111025-46-8, Pioglitazone 111223-26-8, Ceranapril 113665-84-2, Clopidogrel 114798-26-4, Losartan 114977-28-5, Docetaxel 116644-53-2, Mibefradil 116680-01-4, CellCept 117091-64-2, Etoposide phosphate 120014-06-4, Donepezil 121181-53-1, Filgrastim 122111-03-9, Gemcitabine hydrochloride 122320-73-4, Rosiglitazone 123441-03-2, Exelon 123774-72-1, Sargramostim 123948-87-8, Topotecan 125317-39-7, Vinorelbine tartrate 127779-20-8, Saquinavir 129318-43-0, MK-217 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 135062-02-1, Repaglinide 137109-78-5, OR1384 137862-53-4, Valsartan 138402-11-6, Irbesartan 139755-83-2, Sildenafil 141626-36-0, Dronedarone 141750-63-2, Nisvastatin 143443-90-7, Ifetroban 143653-53-6, Abciximab 144494-65-5, Tirofiban 147030-48-6, KB-130015 147191-91-1, Priliximab 147511-69-1, Itavastatin 149845-06-7, Saquinavir mesylate 150322-43-3, CS-747 155213-67-5, Ritonavir 157810-81-6, Indinavir sulfate 158861-67-7, Ghrp-2 159183-92-3, L750355 159752-10-0, MK-677 160135-92-2, Gemopatrilat 162011-90-7, Vioxx 164301-51-3, CNI-1493 167305-00-2, Omapatrilat 169590-42-5, Celebrex 170277-31-3, Infliximab
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of sulfonylpyrrolidines as modulators of androgen receptor)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:824492 CAPLUS
DOCUMENT NUMBER: 143:222525
TITLE: Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function, preparation thereof, and use with other agents
INVENTOR(S): Nirschl, Alexandra A.; Hamann, Lawrence G.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005182105	A1	20050818	US 2005-48437	20050201
PRIORITY APPLN. INFO.:			US 2004-541780P P	20040204

OTHER SOURCE(S): MARPAT 143:222525
ED Entered STN: 19 Aug 2005
GI



I

AB A method is provided for treating androgen receptor-associated conditions,

such as age-related diseases, e.g. sarcopenia, employing a compound I [R1 = CN, H; X = O, S; R2 = (substituted) alkyl, (substituted) cycloalkyl, etc; R3, R4 = H, (substituted) alkyl, etc.; G = (substituted) aryl, (substituted) heteroaryl], or a **pharmaceutically** acceptable salt or prodrug ester thereof. Preparation of selected I is described. I may be used in combination with other agents.

IC ICM A61K031-4439
ICS A61K031-44
INCL 514340000; 514344000
CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 27
IT 5-HT reuptake inhibitors
AIDS (disease)
Acne
Alkylating agents, biological
Alopecia
Alzheimer's disease
Anabolic agents
Anemia (disease)
Anorexia
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiandrogens
Antiarthritics
Antibiotics
Anticholesteremic agents
Anticoagulants
Antidepressants
Antidiabetic agents
Antiestrogens
Antihypertensives
Antiobesity agents
Antitumor agents
Antiviral agents
Anxiety
Anxiolytics
Appetite depressants
Bladder, neoplasm
Bone resorption inhibitors
Brain, neoplasm
Burn
Calcium channel blockers
Cardiovascular agents
Chemotherapy
Cognition enhancers
Cognitive disorders
Coma
Combination chemotherapy
Contraceptives
Cushing's syndrome
Cytotoxic agents
Diabetes mellitus
Diuretics
Drug delivery systems
Eating disorders
GABA antagonists
Gastrointestinal agents
Hirsutism
Hormone replacement therapy

Human
Human immunodeficiency virus
Hypercholesterolemia
Hypertension
Hypolipemic agents
Hypothermia
Immunomodulators
Immunosuppression
Inflammation
Kidney, neoplasm
Lipodystrophy
Liver, neoplasm
Lung, neoplasm
Lymphatic system, neoplasm
Mammary gland, neoplasm
Musculoskeletal diseases
Mycobacterium BCG
Nervous system agents
Obesity
Osteoarthritis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Periodontium, disease
Platelet aggregation inhibitors
Potassium channel openers
Preeclampsia
Pregnancy
Prophylaxis
Prostate gland, neoplasm
Radiotherapy
Seborrhea
Selective estrogen receptor modulators
Sexual disorders
Skin, neoplasm
Sleep disorders
Spermatogenesis
Stress, animal
Thrombolytics
Thrombosis
Thromboxane receptor antagonists
Wound
Wound healing promoters
(cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

IT 5-HT receptors
Amino acids, biological studies
Androgens
Caseins, biological studies
Enkephalins
Enzymes, biological studies
Fibrates
Glucocorticoids
Glycerides, biological studies
Hormones, animal, biological studies
Interferons
Interleukins
Minerals, biological studies
Natural products, **pharmaceutical**
Nitrates, biological studies

Steroids, biological studies
Sulfonylureas
Taxanes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

IT Natural products, **pharmaceutical**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis; cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

IT 50-02-2, Dexamethasone 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 51-21-8, Fluorouracil 51-64-9, Dexamphetamine 52-01-7, Spironolactone 52-24-4, Thiotepa 52-53-9, Verapamil 53-03-2, Prednisone 53-19-0, Mitotane 53-43-0, Dehydroepiandrosterone 53-86-1, Indomethacin 54-31-9, Furosemide 55-86-7, Nitrogen mustard 55-98-1, Busulfan 56-03-1D, Biguanide, derivs. 56-53-1 57-22-7, Vincristine 57-47-6, Physostigmine 57-83-0, Progestin, biological studies 58-32-2, Dipyridamole 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 60-27-5, Creatinine 61-90-5, Leucine, biological studies 68-19-9, Vitamin B12 71-58-9, Medroxyprogesterone acetate 73-31-4D, Melatonin, analogs 73-48-3, Bendroflumethiazide 77-36-1, Chlorthalidone 91-18-9 D, Pteridine, derivs. 91-33-8, Benzthiazide 120-73-0D, Purine, analogs 122-09-8, Phentermine 127-07-1, Hydroxyurea 133-67-5, Trichloromethiazide 135-07-9 135-09-1, Hydroflumethiazide 147-94-4, Cytarabine 148-56-1, Flumethiazide 148-82-3, Melphalan 151-56-4D, Ethylenimine, derivs. 154-42-7, Thioguanine 154-93-8, Carmustin 155-97-5, Pyridostigmine 289-95-2D, Pyrimidine, analogs 302-79-4, Retinoic acid 303-98-0, Coenzyme Q-10 305-03-3, Chlorambucil 321-64-2, Tacrine 346-18-9, Polythiazide 378-44-9, Betamethasone 396-01-0, Triamterene 439-14-5, Diazepam 541-15-1, Carnitine 595-33-5, Megestrol acetate 604-75-1, Oxazepam **625-08-1** 630-60-4, Ouabain 645-05-6, Hexamethylmelamine 657-24-9, Metformin 671-16-9, Procarbazine 797-63-7, Levonorgestrel 846-49-1, Lorazepam 865-21-4, Vinblastine 1404-00-8, Mitomycin 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, analogs 1406-18-4, Vitamin E 2030-63-9, Clofazimine 2295-31-0D, Thiazolidinedione, derivs. 2609-46-3, Amiloride 2998-57-4, Estramustine 3056-17-5, Stavudine 3778-73-2, Ifosfamide 4205-90-7, Clonidine 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4375-07-9, Epipodophyllotoxin 5630-53-5, Tibolone **7439-95-4**, Magnesium, biological studies 7440-06-4D, Platinum, coordination complexes 7440-09-7, Potassium, biological studies 7440-47-3, Chromium, biological studies 7440-66-6, Zinc, biological studies **7440-70-2**, Calcium, biological studies 7481-89-2, Zalcitabine 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9002-64-6, Parathyroid hormone 9002-64-6D, PTH, fragments 9002-71-5, Thyrotropin 9002-72-6D, Growth hormone, analogs 9007-12-9, Calcitonin 9015-68-3, L-Asparaginase 9034-39-3, Growth hormone releasing factor 9034-39-3D, Growth hormone releasing factor, analogs 9038-70-4, Somatomedin 9041-93-4, Bleomycin sulfate 10238-21-8, Glyburide 10246-75-0, Hydroxyzine pamoate 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 11103-57-4, Vitamin A 13010-20-3D, Nitrosourea, derivs. 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 15056-34-5D, Triazene, derivs. 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 16984-48-8, Fluoride, biological studies 18378-89-7,

Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 24305-27-9, TRH 25316-40-9, Adriamycin 26027-38-3, Nonoxynol 9 26538-44-3, Zeranol 28395-03-1, Bumetanide 29094-61-9, Glipizide 29767-20-2, Teniposide 30516-87-1, Zidovudine 33069-62-4, Taxol 33069-62-4D, Taxol, analogs 33419-42-0, Etoposide 35212-22-7, Ipriflavone 36085-73-1, B-HT920 36322-90-4, Piroxicam 36505-84-7, Buspirone 38304-91-5, Minoxidil 40180-04-9 41575-94-4, Carboplatin 42399-41-7, Diltiazem 51333-22-3, Budesonide 52205-73-9, Estramustine phosphate sodium 52232-67-4 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54870-28-9, Meglitinide 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55294-15-0, Muzolimine 56180-94-0, Acarbose 57828-26-9, Lipoic acid 57982-77-1, Buserelin 58095-31-1, Sulbenox 58957-92-9, Idarubicin 59729-33-8, Citalopram 59865-13-3, Cyclosporin A 61869-08-7, Paroxetine 62571-86-2, Captopril 66376-36-1, Alendronate 67763-96-6, IGF-1 67763-97-7, IGF-2 69655-05-6, Didanosine 73963-72-1, Cilostazol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79392-34-0, Saframycin 79517-01-4, Octreotide acetate 79617-96-2, Sertraline 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81872-10-8, Zofenopril 82924-03-6, Pentopril 83366-66-9, Nefazodone 83435-66-9, Delapril 84449-90-1, Raloxifene 84573-33-1, Quinocarcin 85441-61-8, Quinapril 87333-19-5, Ramipril 87616-84-0 88150-42-9, Amlodipine 88768-40-5 89750-14-1, GLP-1 93479-97-1, Glimepiride 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 98319-26-7, Finasteride 100286-90-6, Irinotecan hydrochloride 103628-46-2, Sumatriptan 104987-11-3, FK-506 105462-24-6 106650-56-0, Sibutramine 110942-02-4, Aldesleukin 111025-46-8, Pioglitazone 111223-26-8, Ceranapril 113665-84-2, Clopidogrel 114798-26-4, Losartan 114977-28-5, Taxotere 114977-28-5D, Taxotere, analogs 116644-53-2, Mibefradil 117091-64-2, Etoposide phosphate 118390-30-0 120014-06-4, Donepezil 121181-53-1, Filgrastim 122111-03-9, Gemcitabine hydrochloride 122320-73-4, Rosiglitazone 123441-03-2, Rivastigmine 123774-72-1, Sargramostim 123948-87-8, Topotecan 123948-87-8D, Topotecan, derivs. 125317-39-7, Vinorelbine tartrate 127779-20-8, Saquinavir 127943-53-7, Discodermolide 129318-43-0, MK-217 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 135062-02-1, Repaglinide 137109-78-5, OR1384 137862-53-4, Valsartan 138402-11-6, Irbesartan 139755-83-2, Sildenafil 141626-36-0, Dronedarone 141750-63-2, Nisvastatin 141925-59-9, GHRP-1 143443-90-7, Ifetroban 143653-53-6, Abciximab 144494-65-5, Tirofiban
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyanoarylpyridine derivative modulators of androgen receptor function, preparation, and use with other agents)

L28 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:936114 CAPLUS
DOCUMENT NUMBER: 141:400914
TITLE: Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
INVENTOR(S): Wiley, David B.; Dobbins, Thomas A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 658,075.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004220266	A1	20041104	US 2004-797946	20040311
US 2004048925	A1	20040311	US 2003-658075	20030909
PRIORITY APPLN. INFO.:			US 2002-409151P	P 20020909
			US 2003-658075	A2 20030909

ED Entered STN: 06 Nov 2004

AB Dietary mineral supplements comprising the calcium and/or magnesium salts of 3-hydroxy-3-methylbutyric acid are disclosed as efficient means of orally administering calcium and/or magnesium in order to prevent or treat calcium and magnesium deficiency pathologies. The conjoint bioavailability of these important minerals is thereby enhanced. Thus, 74.1 g of calcium hydroxide and 20.15 g of magnesium oxide were added to 500 mL of water with vigorous agitation, forming a slurry. Then, 336 g of 3-methyl-3-hydroxy-3-methylbutyric acid was introduced slowly and the mixture was heated to 70° degrees C. and stirred for 90 min, then allowed to cool to room temperature Insol. particles of excess lime and magnesia were removed by filtration and the filtrate, was evaporated to dryness, producing an intimate mixture of crystalline calcium 3-hydroxy-3-methylbutyrate monohydrate and magnesium 3-hydroxy-3-methylbutyrate in virtually quant. yield. Varying amts. of calcium hydroxymethlbutyrate was administered orally in the form of capsules to volunteers. Nine of ten subjects exhibited significantly elevated levels of serum calcium two hours after ingesting 1,000 mg of calcium hydroxymethylbutyrate, thereby demonstrating absorption and metabolic availability of calcium.

IC ICM A61K031-19

INCL 514557000

CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 17

IT **176389-82-5 786710-98-3**
RL: FFD (Food or feed use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for enhancing bioavailability of calcium and magnesium in dietary supplements and food additives)

L28 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:451640 CAPLUS

DOCUMENT NUMBER: 141:12301

TITLE: Compositions for the **parenteral** administration of calcium and magnesium

INVENTOR(S): Dobbins, Thomas A.; Wiley, David B.; Davis, Michael

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004106678	A1	20040603	US 2003-667283	20030917
WO 2005096846	A1	20051020	WO 2004-US7452	20040311

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG
PRIORITY APPLN. INFO.: US 2002-411229P P 20020917
ED Entered STN: 04 Jun 2004
AB Aqueous solns. of the calcium and/or magnesium salts of 3-hydroxy-3-methylbutyric acid are useful for **parenteral** administration of the calcium and/or magnesium in the treatment and prevention of disorders caused by or accompanied by **hypocalcemia** or **hypomagnesia** . The salts were prepared from Ca(OH)2 and MgO, resp. and 3-methyl-3-hydroxybutyric acid.
IC ICM A61K031-19
INCL 514557000
CC **63-6** (Pharmaceuticals)
ST **parenteral** compn calcium magnesium
IT **Drug delivery** systems
(**parenterals**; compns. for the **parenteral** administration of calcium and magnesium)
IT **625-08-1**, 3-Hydroxy-3-methylbutyric acid 1305-62-0, Calcium hydroxide, reactions 1309-48-4, Magnesium oxide, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. for the **parenteral** administration of calcium and magnesium)
IT **625-08-1DP**, magnesium salt **176389-82-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. for the **parenteral** administration of calcium and magnesium)
IT **14127-61-8**, Calcium ion, biological studies **22537-22-0**, Magnesium ion, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for the **parenteral** administration of calcium and magnesium)

L28 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:310653 CAPLUS
DOCUMENT NUMBER: 140:320327
TITLE: Agglomerated granular protein-rich nutritional supplement
INVENTOR(S): Lockwood, Christopher
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004071825	A1	20040415	US 2002-271239	20021015
WO 2004034986	A2	20040429	WO 2003-US32646	20031015
WO 2004034986	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-271239 A 20021015

ED Entered STN: 16 Apr 2004

AB An agglomerated granular protein-rich nutritional supplement comprises a mixture of: 13-100 percent by weight edible food proteins; 0-57 percent by weight edible carbohydrates; 0-10 percent by weight edible fats; 0-15 percent by weight edible dietary vitamins and minerals; 0-78 percent by weight edible amino acids; 0-10 percent by weight edible plant exts., and up to 4 percent by weight chondroitin sulfate, where the nutritional supplement is agglomerated and granulated in an oral unit dosage form that is directly absorbable onto the tongue or rapidly dissolvable in an aqueous liquid Specific formulations of the supplement are disclosed, for use by specific groups of individuals. A method of supplementing the nutritional intake of individuals engaged in bodybuilding and protein supplementation, meal replacement, exercise recovery or mass gaining, comprising orally administering a formulation of the protein-rich nutritional supplement. A method of augmenting the mental acuity and energy of humans, comprising orally administering another formulation of the protein-rich nutritional supplement. Methods also are disclosed for supplementing the nutritional intake of women, male bodybuilders, children and adolescents, and older adults. In all methods, the nutritional supplement is in an oral unit dosage form of either agglomerated granules or a rapidly dissolvable wafer and also includes a flavoring compound and an effervescing compound

IC ICM A23L001-30

INCL 426072000; 426656000

CC 17-6 (Food and Feed Chemistry)
Section cross-reference(s): 18, **63**

IT Agglomeration
Angelica sinensis
Cranberry
Dietary fiber
Drug delivery systems
Egg white
Flavor
Flavoring materials
Food additives
Growth, animal
Health food
Human
Mucuna pruriens
Nutrients
Sweetening agents
(agglomerated granular protein-rich nutritional supplement)

IT **Drug delivery** systems
(effervescent wafers; agglomerated granular protein-rich nutritional supplement)

IT **Drug delivery** systems
(effervescent; agglomerated granular protein-rich nutritional supplement)

IT **Drug delivery** systems
(granules; agglomerated granular protein-rich nutritional supplement)

IT Effervescent materials
(**pharmaceuticals**; agglomerated granular protein-rich nutritional supplement)

IT 50-69-1, Ribose 50-81-7, Vitamin C, biological studies 50-99-7, Dextrose, biological studies 56-41-7, L-Alanine, biological studies 56-85-9, Glutamine, biological studies 56-85-9D, L-Glutamine, peptides containing 56-87-1, Lysine, biological studies 57-00-1, Creatine 57-48-7, Fructose, biological studies 58-08-2, Caffeine, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 60-18-4, Tyrosine, biological studies 61-90-5, L-Leucine, biological studies 63-91-2, Phenylalanine, biological studies 68-19-9, Vitamin B12 70-47-3, L-Asparagine, biological studies 72-18-4, Valine, biological studies 73-32-5, L-Isoleucine, biological studies 74-79-3, Arginine, biological studies 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 98-79-3, Pyroglutamic acid 107-35-7, Taurine 108-01-0, DMAE 127-17-3D, Pyruvic acid, derivs. 146-48-5, Yohimbine **625-08-1**, β-Hydroxy-β-methylbutyric acid 1406-16-2, Vitamin D 1406-18-4, Vitamin E 3416-24-8, Glucosamine 4151-33-1, Potassium pyruvate 4547-24-4 6020-87-7, Creatine monohydrate 6217-54-5, Docosahexaenoic acid 7235-40-7, β-Carotene 7439-89-6, Iron, biological studies **7439-95-4**, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7439-98-7, Molybdenum, biological studies 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies **7440-70-2**, Calcium, biological studies 7553-56-2, Iodine, biological studies 7723-14-0, Phosphorus, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9050-36-6, Maltodextrin 10284-63-6, Inzitol 10417-94-4, Eicosapentaenoic acid 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12001-79-5, Vitamin K 14265-44-2, Phosphate, biological studies 16887-00-6, Chloride, biological studies 34414-83-0, Ornithine α-ketoglutarate 52009-14-0, Calcium pyruvate 55399-93-4 56038-13-2, Splenda 72087-40-2
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agglomerated granular protein-rich nutritional supplement)

L28 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:203561 CAPLUS
DOCUMENT NUMBER: 140:234740
TITLE: Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
INVENTOR(S): Wiley, David B.; Dobbins, Thomas A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004048925	A1	20040311	US 2003-658075		20030909
US 2004220266	A1	20041104	US 2004-797946		20040311
PRIORITY APPLN. INFO.:			US 2002-409151P	P	20020909
			US 2003-658075	A2	20030909

ED Entered STN: 14 Mar 2004
AB Dietary mineral supplements comprise calcium and/or magnesium salts of 3-hydroxy-3-methylbutyric acid are disclosed as efficient means of orally administering calcium and/or magnesium in order to prevent or treat calcium and magnesium deficiency pathologies. The conjoint bioavailability of these important minerals is thereby enhanced.
IC ICM A61K031-19
INCL 514557000
CC 17-6 (Food and Feed Chemistry)
Section cross-reference(s): 18, **63**
IT **625-08-1D**, 3-Hydroxy-3-methylbutyric acid, salts **7439-95-4**, Magnesium, biological studies **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhanced calcium and magnesium bioavailability in dietary supplements and food additives)

L28 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:1003415 CAPLUS
DOCUMENT NUMBER: 140:4391
TITLE: Nutritionally active compositions for body building and beverages providing psychological feedback
INVENTOR(S): Krotzer, R. Douglas
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001008641	A1	20010719	US 1998-199433	19981125
PRIORITY APPLN. INFO.:			US 1998-199433	19981125

ED Entered STN: 25 Dec 2003
AB Nutritionally beneficial compns. for body building comprise a component selected from the group consisting of creatine monohydrate, HMB (β-hydroxy-β-methylbutyrate), L-glutamine, taurine, whey peptides, chromium, potassium, phosphorus, and magnesium and ≥1 addnl. component that stimulates short- and/or long-term psychol. feedback (e.g. caffeine, tryptophan, citric acid, or quinine). The compns., for oral or translingual delivery, are formulated preferably as a beverage.
IC ICM A61K035-78
INCL 424725000; 424729000; 424075000; 424734000
CC 17-13 (Food and Feed Chemistry)
Section cross-reference(s): 18, **63**
IT **Drug delivery** systems
(oral; nutritionally and psychol. active compns. for body building)
IT 50-67-9, Serotonin, biological studies 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 51-43-4, Epinephrine 54-47-7, Pyridoxal-5-phosphate 56-12-2, GABA, biological studies 56-85-9, L-Glutamine, biological studies 56-86-0, L-Glutamic acid, biological studies 57-00-1, Creatine 57-48-7, D-Fructose, biological studies 57-50-1, Sucrose, biological studies 58-08-2, Caffeine, biological studies 58-55-9, Theophylline, biological studies 59-23-4, Galactose, biological studies 59-67-6D, Nicotinic acid, chromium complexes 60-18-4, L-Tyrosine, biological studies 63-42-3, Lactose 63-91-2, L-Phenylalanine, biological studies 69-79-4, Maltose 73-22-3,

Tryptophan, biological studies 77-92-9, Citric acid, biological studies 81-07-2, Saccharin 83-67-0, Theobromine 90-82-4 100-88-9D, Cyclamate, derivs. 107-35-7, Taurine 130-86-9, Protopine 130-95-0, Quinine 150-30-1, Phenylalanine 299-42-3, Ephedrine 463-79-6, Carbonic acid, biological studies 485-91-6 520-52-5, Psilocybin **625-08-1**, β-Hydroxy-β-methylbutyric acid 712-08-3, 5-Fluoro-α-methyltryptamine 4350-09-8 6020-87-7, Creatine monohydrate 6915-15-7, Malic acid **7439-95-4**, Magnesium, biological studies 7440-09-7, Potassium, biological studies 7440-47-3, Chromium, biological studies 7440-47-3D, Chromium, polynicotinate complexe 7440-66-6, Zinc, biological studies **7440-70-2**, Calcium, biological studies 7664-38-2, Phosphoric acid, biological studies 7723-14-0, Phosphorus, biological studies 14639-25-9 16626-02-1, 5-Fluorotryptophan 19310-00-0 22839-47-0, Aspartame 28109-92-4D, Methylxanthine, derivs. 94421-68-8D, Anandamide, derivs.
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional compns. providing psychol. feedback for body building)

L28 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:511160 CAPLUS
DOCUMENT NUMBER: 139:63365
TITLE: Use of hyperforin or St. John's wort extracts for the treatment of anaphylactic shock and for maintaining and improving bone health
INVENTOR(S): Werz, Oliver; Albert, Dana; Steinhilber, Dieter; Bock, Andreas
PATENT ASSIGNEE(S): Phenion GMBH & Co. KG, Germany
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003053456	A1	20030703	WO 2002-EP14207		20021213
W: AU, BR, BY, CA, CN, DZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RO, RU, SG, UA, US, UZ, VN, YU, ZA					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR					
DE 10163676	A1	20030710	DE 2001-10163676		20011221
AU 2002358698	A1	20030709	AU 2002-358698		20021213
PRIORITY APPLN. INFO.:			DE 2001-10163676	A	20011221
			WO 2002-EP14207	W	20021213

ED Entered STN: 04 Jul 2003
AB The invention discloses the use of hyperforin or St. John's wort (hypericum) exts. for the prophylaxis and/or therapy of anaphylactic shock and for maintaining and improving bone health, particularly for treating osteoporosis, and as a nutritional supplement and for **pharmaceutical** prepns. containing hyperforin or St John's wort extract
IC ICM A61K035-78
ICS A61P019-08; A61P019-10; A61P043-00
CC 1-12 (Pharmacology)
Section cross-reference(s): 18, **63**
IT **Drug delivery** systems
(aerosols; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems

(buccal; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(capsules; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(emulsions; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT Adrenoceptor agonists
Anaphylaxis
Antiasthmatics
Apoptosis
Bone
Bronchodilators
Drug delivery systems
Human
Hypericum
Macrophage
Monocyte
Osteoclast
Platelet (blood)
Polymorphonuclear leukocyte
(hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT Fluorides, biological studies
Natural products, **pharmaceutical**
Paraffin oils
Vitamins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(inhalants; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(injections, i.m.; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(injections, i.p.; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(injections, i.v.; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(injections, s.c.; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(intraarticular; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(nasal; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(ointments, creams; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems
(ointments; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
IT **Drug delivery** systems

(oral; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT **Drug delivery** systems
(rectal; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT **Drug delivery** systems
(solns.; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT **Drug delivery** systems
(suppositories; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT **Drug delivery** systems
(suspensions; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT **Drug delivery** systems
(tablets; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT **Drug delivery** systems
(topical; hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)

IT 50-18-0, Cyclophosphamide 50-21-5, Lactic acid, biological studies 50-33-9, Phenylbutazone, biological studies 50-96-4 52-67-5, D-Penicillamine 53-86-1, Indomethacin 54-05-7, Chloroquine 56-81-5, Glycerin, biological studies 56-85-9, Glutamine, biological studies 57-00-1, Creatine 57-13-6, Urea, biological studies 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 61-68-7, Mefenamic acid 64-19-7D, Acetic acid, aryl derivs. 68-19-9, Vitamin B12 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 79-09-4D, Propionic acid, aryl derivs. 97-59-6, Allantoin 107-35-7, Taurine 110-17-8, Fumaric acid, biological studies 112-38-9, Undecylenic acid 118-42-3, Hydroxychloroquine 118-92-3D, Anthranilic acid, derivs. 120-72-9D, Indole, derivs. 129-20-4, Oxyphenbutazone 288-13-1D, Pyrazole, derivs. 298-81-7, Ammoidin 305-03-3, Chlorambucil 446-86-6, Azathioprine 530-78-9, Flufenamic acid 599-79-1, Sulfasalazine **625-08-1** 642-72-8, Benzydamine 1143-38-0, Dithranol 1200-22-2, α-Lipoic acid 1306-23-6, Cadmium sulfide, biological studies 1314-13-2, Zinc oxide, biological studies 1406-05-9, Penicillin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1944-12-3, Fenoterol hydrobromide 2139-47-1, Nifenazone 2210-63-1, Mofebutazone 2438-72-4, Bufexamac 3583-64-0, Bumadizone 4394-00-7, Nifluminic acid 4985-25-5, Pyrazinobutazone 4991-65-5, Tioxolone 5104-49-4 5874-97-5, Orciprenaline sulfate **7440-70-2D**, Calcium, salts 7704-34-9, Sulfur, biological studies 9001-54-1, Hyaluronidase 9054-89-1, Orgotein 11079-53-1, Hyperforin 11103-57-4, Vitamin A 12192-57-3 12244-57-4 13055-82-8, Reproterol hydrochloride 13539-59-8, Azapropazone 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 16903-35-8 21898-19-1, Clenbuterol hydrochloride 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22457-89-2, Benfotiamine 22881-35-2, Famprofazone 23031-32-5, Terbutaline sulfate 26171-23-3, Tolmetin 26183-44-8 29031-19-4, Glucosamine sulfate 29679-58-1, Fenoprofen 29908-03-0, Ademetionine 30544-47-9, E-Tofenamate 31793-07-4, Pirprofen 33005-95-7, Tiaprofenic acid 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34866-46-1, Carbuterol hydrochloride 36322-90-4, Piroxicam 36330-85-5, Fenbufen 38029-10-6, Pirbuterol hydrochloride 42924-53-8, Nabumetone 51022-70-9, Salbutamol sulfate 53164-05-9, Acemetacin 53716-49-7, Carprofen 53808-88-1, Lonazolac 54350-48-0, Etretinate 56776-01-3, Tulobuterol hydrochloride 57132-53-3, Proglumetacin 62929-91-3, Procaterol hydrochloride 95077-02-4, Serrapeptase
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(hyperforin or St. John's wort exts. for treatment of anaphylactic shock and for maintaining and improving bone health)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:171618 CAPLUS
DOCUMENT NUMBER: 136:215851
TITLE: Method for preparing a mixture that can be granulated, especially carnitine-magnesium hydroxycitrate
INVENTOR(S): Fuhrmann, Martin; Pianzola, Daniel
PATENT ASSIGNEE(S): Lonza Ag, Switz.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017735	A2	20020307	WO 2001-EP9962	20010829
WO 2002017735	A3	20020912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001089849	A5	20020313	AU 2001-89849	20010829
EP 1326502	A2	20030716	EP 2001-969667	20010829
EP 1326502	B1	20050518		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507479	T2	20040311	JP 2002-522720	20010829
AT 295690	E	20050615	AT 2001-969667	20010829
PT 1326502	T	20050930	PT 2001-969667	20010829
ES 2242770	T3	20051116	ES 2001-1969667	20010829
US 2003176514	A1	20030918	US 2003-362730	20030514
US 2004167219	A1	20040826	US 2004-785013	20040225

PRIORITY APPLN. INFO.:	EP 2000-118656	A	20000829
	WO 2001-EP9962	W	20010829
	US 2003-362730	A3	20030514

ED Entered STN: 08 Mar 2002
AB The invention relates to a method for preparing, from at least one hygroscopic substance, mixts. that can be granulated and that have little hygroscopicity. The invention further relates to the corresponding mixts., especially carnitine-magnesium citrate and carnitine-magnesium hydroxycitrate.
IC ICM A23L001-302
ICS A61K031-205
CC 17-6 (Food and Feed Chemistry)
Section cross-reference(s): **63**
IT **Drug delivery** systems
(granules; method for preparing a mixture that can be granulated, especially carnitine-magnesium hydroxycitrate)

IT **Drug delivery** systems
(pastes; method for preparing a mixture that can be granulated, especially carnitine-magnesium hydroxycitrate)
IT 50-69-1, Ribose 59-67-6, Niacin, biological studies 98-92-0, Nicotinamide 303-98-0, Coenzyme Q10 **625-08-1**, 3-Hydroxy-3-methyl butyric acid 1200-22-2, Lipoic acid 16065-83-1D, Chromium (III), salts, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(method for preparing a mixture that can be granulated, especially carnitine-magnesium hydroxycitrate)
IT 541-15-1, L-Carnitine 541-15-1D, Carnitine, derivs. **7439-95-4D**, Magnesium, hydroxycitric acid salt **7440-70-2D**, Calcium, carnitine-containing salts 7779-25-1, Magnesium citrate
RL: FFD (Food or feed use); PEP (Physical, engineering or chemical process); PYP (Physical process); BIOL (Biological study); PROC (Process); USES (Uses)
(method for preparing a mixture that can be granulated, especially carnitine-magnesium hydroxycitrate)

L28 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:687450 CAPLUS
DOCUMENT NUMBER: 135:236451
TITLE: Method using β-hydroxy-β-methylbutyric acid for improving a human's perception of his emotional state
INVENTOR(S): Nissen, Steven L.
PATENT ASSIGNEE(S): Iowa State University Research Foundation, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6291525	B1	20010918	US 1999-391830	19990908
PRIORITY APPLN. INFO.:			US 1999-391830	19990908

ED Entered STN: 20 Sep 2001
AB The invention provides a method for improving a human's perception of his emotional state. The method comprises administering β-hydroxy-β-methylbutyric acid to the human in an amount sufficient to improve his perception of his emotional state. The method can further comprise co-administering arginine and glutamine and/or engaging the human in non-resistance training.
IC ICM A61K031-19
INCL 514557000
CC 1-11 (Pharmacology)
IT AIDS (disease)
Beverages
Drug delivery systems
Emotion
(β-hydroxy-β-methylbutyric acid for improving human perception of emotional state)
IT 56-85-9, Glutamine, biological studies 74-79-3, Arginine, biological studies 625-08-1 625-08-1D, chromium complex 625-08-1D, esters, lactones,and salts 1823-52-5 6149-45-7 7440-47-3D, Chromium, β-hydroxy-β-methylbutyrate complex, biological studies 18267-36-2 **135236-72-5** 155206-13-6 155206-14-7 159804-18-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β-hydroxy-β-methylbutyric acid for improving human perception of emotional state)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:597761 CAPLUS
DOCUMENT NUMBER: 135:170782
TITLE: **Pharmaceutical** composition for muscular anabolism
INVENTOR(S): Smeets, Rudolf Leonardus Lodewijk; Hageman, Robert Johan Joseph
PATENT ASSIGNEE(S): N.V. Nutricia, Neth.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058284	A1	20010816	WO 2001-NL112	20010212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6521591	B1	20030218	US 2000-500802	20000210
CA 2398990	AA	20010816	CA 2001-2398990	20010212
EP 1253830	A1	20021106	EP 2001-910231	20010212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-500802 A 20000210
WO 2001-NL112 W 20010212

ED Entered STN: 17 Aug 2001

AB A **pharmaceutical** composition suitable for enhancing muscular anabolism contains, per daily dose, at least 5 mg of anabolic initiators comprising anabolic growth factors, at least 0.12 g of protein equivalent of anabolic substrates and at least 3 g of anabolic facilitators comprising at least 1 g of creatine or its functional equivalent The anabolic initiators may be derived from a non-denatured animal protein, non-denatured being defined as having a F0 of less than 3.0.

IC ICM A23L001-305
ICS A23L001-302; A61K035-20

CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 18

IT Metabolism
(anabolic; **pharmaceutical** composition for muscular anabolism)

IT Amino acids, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(branched; **pharmaceutical** composition for muscular anabolism)

IT Proteins, general, biological studies

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(milk; **pharmaceutical** composition for muscular anabolism)

IT Colostrum
Drug delivery systems
Muscle
(**pharmaceutical** composition for muscular anabolism)

IT Amino acids, biological studies
Carbohydrates, biological studies
Proteins, general, biological studies
Vitamins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmaceutical** composition for muscular anabolism)

IT Diet
(supplements; **pharmaceutical** composition for muscular anabolism)

IT 56-87-1, L-Lysine, biological studies 59-30-3, Folic acid, biological studies 61-90-5, L-Leucine, biological studies 63-68-3, L-Methionine, biological studies 68-19-9, vitamin b12 73-22-3, L-Tryptophan, biological studies 73-31-4, Melatonin **625-08-1**, Butanoic acid, 3-hydroxy-3-methyl- **7439-95-4**, Magnesium, biological studies 7440-66-6, Zinc, biological studies 8059-24-3, vitamin b6
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**pharmaceutical** composition for muscular anabolism)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:819233 CAPLUS
DOCUMENT NUMBER: 132:45006
TITLE: Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
INVENTOR(S): Nissen, Steven L.; Abumrad, Naji M.
PATENT ASSIGNEE(S): Iowa State University Research Foundation, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966917	A2	19991229	WO 1999-US14097	19990623
WO 9966917	A3	20000420		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6031000	A	20000229	US 1998-102941	19980623
CA 2334761	AA	19991229	CA 1999-2334761	19990623
AU 9947080	A1	20000110	AU 1999-47080	19990623
AU 756353	B2	20030109		

EP 1089726	A2	20010411	EP 1999-930567		19990623
EP 1089726	B1	20020502			
R: BE, DE, DK, ES, FR, GB, IT, NL, SE					
JP 2002518440	T2	20020625	JP 2000-555603		19990623
ES 2177293	T3	20021201	ES 1999-930567		19990623
NZ 508395	A	20030926	NZ 1999-508395		19990623
NO 2000006633	A	20010220	NO 2000-6633		20001222
PRIORITY APPLN. INFO.:			US 1998-102941	A	19980623
			WO 1999-US14097	W	19990623

ED Entered STN: 30 Dec 1999

AB The present invention provides a composition comprising β-hydroxy-β-methylbutyric acid (HMB) and at least one amino acid. The present invention also provides a method for the treatment of disease-associated wasting of an animal, a method for decreasing the serum level of triglycerides of an animal, a method for decreasing the serum viral load of an animal, a method for redistributing fat in an animal having a visceral region and a s.c. region, a method for increasing the lean tissue mass of an animal without substantially decreasing the fat mass of the animal, and a method for increasing the HDL cholesterol level of an animal. All methods comprise administering to the animal a composition comprising HMB and at least one amino acid.

IC ICM A61K031-00

CC 1-12 (Pharmacology)
Section cross-reference(s): 18, **63**

IT **Drug delivery** systems
(oral, powders; nutritional supplements containing β-hydroxy-β-methylbutyrate and amino acids for increasing HDL)

IT 52-90-4, L-Cysteine, biological studies 56-40-6, Glycine, biological studies 56-85-9, L-Glutamine, biological studies 56-87-1, L-Lysine, biological studies 61-90-5, L-Leucine, biological studies 63-68-3, L-Methionine, biological studies 72-18-4, L-Valine, biological studies 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine, biological studies 625-08-1, 3-Hydroxy-3-methylbutyric acid 6149-45-7, Methyl 3-hydroxy-3-methylbutyrate 18267-36-2, Ethyl 3-hydroxy-3-methylbutyrate 34945-05-6, 3-Hydroxy-3-methylbutyrolactone **135236-72-5** 155206-13-6 155206-14-7 159804-18-9 252960-10-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional supplements containing β-hydroxy-β-methylbutyrate and amino acids)

L28 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1994:541664 CAPLUS
DOCUMENT NUMBER:	121:141664
TITLE:	Method of promoting nitrogen retention in humans
INVENTOR(S):	Nissen, Steven L.; Flakkol, Paul J.; Abumrad, Naji N.
PATENT ASSIGNEE(S):	Iowa State University Research Foundation Inc., USA; Vanderbilt University
SOURCE:	PCT Int. Appl., 16 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9414429	A1	19940707	WO 1993-US11993	19931209

	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
US	5348979	A	19940920	US 1992-996187		19921223
CA	2129541	AA	19940707	CA 1993-2129541		19931209
CA	2129541	C	19990511			
AU	9457463	A1	19940719	AU 1994-57463		19931209
AU	664511	B2	19951116			
EP	637239	A1	19950208	EP 1994-903563		19931209
EP	637239	B1	19990811			
	R: AT, DE, ES, FR, GB, IT, NL, SE					
JP	07507569	T2	19950824	JP 1993-515213		19931209
JP	2925326	B2	19990728			
AT	183087	E	19990815	AT 1994-903563		19931209
ES	2134340	T3	19991001	ES 1994-903563		19931209
PRIORITY APPLN. INFO.:				US 1992-996187	A	19921223
				WO 1993-US11993	W	19931209

ED Entered STN: 17 Sep 1994

AB Nitrogen retention in human subjects is promoted by administering β-hydroxy-β-methylbutyric acid (HMB). The amount of HMB administered is effective to conserve protein as determined by reduction in urinary nitrogen. The method can be used with patients having a neg. nitrogen balance due to disease conditions, and also with normal elderly persons who are subject to protein loss. The HMB may be administered orally or by i.v. infusion.

IC ICM A61K031-19

CC **63-5** (Pharmaceuticals)

ST oral **parenteral** hydroxymethylbutyrate protein conservation

IT 625-08-1 6149-45-7 18267-36-2 **135236-72-5** 155206-13-6 155206-14-7 157289-90-2
RL: BIOL (Biological study)
(malnutrition prevention with, by promoting nitrogen retention)

L38 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:169029 CAPLUS

DOCUMENT NUMBER: 142:379286

TITLE: A nutritional and pharmaceutical compositions containing a quinone coenzyme, sugar, and vitamins

INVENTOR(S): Lehmann, Susanna Maria Catrina

PATENT ASSIGNEE(S): Technikon Pretoria, S. Afr.

SOURCE: S. African, 27 pp.
CODEN: SFXXAB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
ZA 2001009677	A	20020625	ZA 2001-9677		20011123
PRIORITY APPLN. INFO.:			ZA 2001-9677	A	20011123
			ZA 2000-4688		20000906

ED Entered STN: 01 Mar 2005

AB A nutritional and pharmaceutical composition which includes at least one quinone coenzyme, at least one sugar, taurine, vitamin C, vitamin E, biotin and at 1 B complex vitamin. Compns. were prepared containing the above compds. including a quinone coenzyme such as 6-(10-hydroxydecyl)-2,3-

dimethoxy-5-methyl-1,4-benzoquinone.
IC ICM A61K
ICS A61P
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): **17**
IT 50-81-7, Vitamin C, biological studies 50-99-7, D-Glucose, biological studies 57-03-4D, Glycerophosphoric acid, derivs. 57-48-7, Fructose, biological studies 58-85-5, Biotin 58-95-7, Tocopherol acetate 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 65-23-6, Pyridoxine 67-71-0, Dimethyl sulfone 68-19-9, Cyanocobalamin 79-83-4, Pantothenic acid 87-89-8, Myoinositol 107-35-7, Taurine 107-43-7D, Betaine, derivs. 541-15-1, Carnitine 616-91-1, N-Acetylcysteine **625-08-1**, 3-Hydroxy-3-methylbutyric acid 1118-68-9, N,N-Dimethylglycine 1332-94-1, Vitamin B17 1406-18-4, Vitamin E 6915-15-7, Malic acid 7235-40-7, β-Carotene 7447-40-7, Potassium chloride, biological studies 7646-85-7, Zinc chloride, biological studies 7786-30-3, Magnesium chloride, biological studies 9000-69-5, Pectin 9004-67-5, Methyl cellulose 12001-76-2, Vitamin B 14007-45-5, Potassium aspartate 18962-61-3, Magnesium aspartate 21059-46-1, Calcium aspartate 29908-03-0 57828-26-9, Lipoic acid 58186-27-9 77712-24-4 77712-32-4 134910-68-2, Lactarin XP 4019 849703-43-1 849703-44-2
RL: **FFD (Food or feed use)**; **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(nutritional and pharmaceutical compns. containing quinone coenzyme and sugar and vitamins)

L38 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:99181 CAPLUS
DOCUMENT NUMBER: 142:183472
TITLE: Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
INVENTOR(S): Boldt, Matthias
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005027005	A1	20050203	US 2003-633232	20030802
PRIORITY APPLN. INFO.:			US 2003-633232	20030802

ED Entered STN: 04 Feb 2005
AB Nutrient compns. and methods that sustain and promote pos. metabolic energy levels in a targeted manner are disclosed. Methods utilize endogenous energy stores (fat oxidation), increase use of those stores (increasing transport rate), increase available energy (increasing the ability to perform ADP to ATP phosphorylation,) as well as decrease catabolism and increase protein synthesis. Compns. are also disclosed, and include mono- or dicreatine-β-hydroxy β-methylbutyrate (HMB) salt; putrescine dihydrochloride; alanine; L-glutamine, which may be combined with alanine in a 1:2 to 2:1 mol. ratio; trimethylglycine; and guanidinopropionic acid.
IC ICM A61K031-205
ICS A61K031-198

INCL 514561000; 514554000
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): **17**
IT 56-41-7, Alanine, biological studies 56-85-9, L-Glutamine, biological studies 107-43-7, Trimethylglycine 333-93-7, Putrescine dihydrochloride 353-09-3, Guanidinopropionic acid **835598-36-2** **835598-38-4**
RL: **FFD (Food or feed use)**; **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(nutrient compns. for promotion of pos. metabolic energy levels)

L38 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:549417 CAPLUS
DOCUMENT NUMBER: 141:111198
TITLE: Cosmetic or pharmaceutical preparations for the improvement of the oxygen uptake in humans and animals using mycosporin-like amino acids, especially Hoshi Nori extract in various formulations
INVENTOR(S): Holtkoetter, Olaf; Gerke, Thomas
PATENT ASSIGNEE(S): Henkel Kgaa, Germany
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259966	A1	20040708	DE 2002-10259966	20021215
PRIORITY APPLN. INFO.:			DE 2002-10259966	20021215

ED Entered STN: 09 Jul 2004
AB The invention concerns the use of mycosporin-like amino acids for the prevention and treatment of hypoxia in humans and animals; cosmetics, pharmaceutical prepns., food and feed supplements are prepared The prepns. are used to treat paradentosis, skin aging, weakness, erectile disfunction etc. The extract of the dried red algae Porphyra, Hoshi Nori is added to various compns. Thus mycosporin-like amino acids were extract from Hoshi Nori with water, followed by dichloromethane extraction, drying, chomatog. and active coal purification The effect on hypoxia-indicating compds. was tested in skin cultures; in the presence of Hoshi Nori extract the expressions of HIF 1α, MMP1, MPP2, lactate dehydrogenase were decreased, the production of ATP synthase and cytochrome C oxidases were increased. Thus a formulation included (weight/weight%): Montanov 68 6.00; Myritol 318 7.00; Stenol 16/18 1.25; Cutina MDV 2.50; Novata AB3.00; Cetiol SB45 1.50; Eusolex 4360 0.50; Tocopherol acetate 0.50; PHB-propylester 0.20; Generol R 0.50; Tego Carbomer (2%) 10.00; Talc 0.50; glycerin 4.50; PHB-methylester 0.20; water to 100; sodium hydroxide (10%) to pH 4.8-5.2; Hoshi Nori primary extract 3.00.
IC ICM A61K035-80
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): **17**, 18, **63**
IT 50-81-7, L-Ascorbic acid, biological studies 57-00-1 58-05-9, 5-Formyltetrahydrofolic acid 58-56-0, Pyridoxin Hydrochloride 58-85-5, Biotin 58-95-7, Tocopherolacetate 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Nicotinic acid, biological studies 60-33-3, Linolic acid, biological studies 67-48-1, Choline chloride 67-97-0, Vitamin D3 68-19-9, Vitamin B12 68-26-8, Vitamin A 70-18-8, Glutathione, biological studies 79-81-2, Vitamin A-Palmitate 83-88-5, Riboflavin, biological studies 98-92-0, Nicotinic

acid amide 127-47-9, Vitamin A-Acetate 134-35-0, 5-Methyltetrahydrofolic acid 135-16-0, Tetrahydrofolic acid 137-08-6, Calcium-Pantothenate 137-66-6, Ascorbylpalmitate 137-86-0, Octotiamine 144-68-3, Zeaxanthin 299-88-7, Bentiamine 463-40-1, Linolenic acid 472-61-7, Astaxanthin 472-70-8, Cryptoxanthin 506-32-1, Arachidonic acid 514-78-3, Canthaxanthin 539-86-6, Diallylthiosulfinate 541-15-1, Carnitine **625-08-1**, β-Hydroxy-β-Methylbutyric acid 804-30-8, Fursultiamine 1107-26-2 1200-22-2, Lipoic acid 1962-15-8D, esters 2800-34-2, 10-Formyltetrahydrofolic acid 3604-90-8, Citranaxanthin 4727-40-6, S-Methylmethionine 5056-12-2 6217-54-5, Docosahexaenoic acid 6829-55-6, Tocotrienol 6983-79-5, Bixin 10417-94-4, Eicosapentaenoic acid 12001-79-5, Vitamin K 17795-26-5, S-Allylcysteine sulfoxide 22457-89-2, Benfotiamine 23061-53-2 23522-05-6, Taurin 29908-03-0 92285-01-3, Ajoene 97451-40-6 97451-41-7 113973-04-9 124505-11-9 134276-34-9
RL: COS (Cosmetic use); **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(cosmetic or pharmaceutical prepns. for improvement of oxygen uptake in humans and animals using mycosporin-like amino acids, especially Hoshi Nori extract in various formulations)

L38 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:310641 CAPLUS
DOCUMENT NUMBER: 140:320585
TITLE: Enhancement of development of oviparous species by in ovo feeding of enteric modulators
INVENTOR(S): Uni, Zehava; Ferket, Peter R.
PATENT ASSIGNEE(S): North Carolina State University, Israel; Yissum Research Development Company of the Hebrew University of Jerusalem
SOURCE: U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. 6,592,878.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004071753	A1	20040415	US 2003-609741	20030630
US 2002035965	A1	20020328	US 2001-919386	20010731
US 6592878	B2	20030715		
WO 2005004918	A1	20050120	WO 2004-US21051	20040629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2000-222744P	P	20000803
	US 2001-919386	A2	20010731
	US 2003-609741	A	20030630

ED Entered STN: 16 Apr 2004
AB The development and growth of oviparous species such as birds is enhanced

by in ovo administration of an enteric modulator such as beta-hydroxy-beta-methylbutyrate (HMB). The enteric modulator is administered into the amnion, where it is then orally ingested by the subject. The enteric modulator enhances the enteric development of the subject prior to hatch, and enhances the growth of the animal before and after hatch.

IC ICM A61K038-17
ICS A61K031-7076; A61K031-198
INCL 424442000; 514557000; 514561000; 514168000; 514458000; 514046000; 514725000; 514008000; 119300000; 514062000
CC 18-6 (Animal Nutrition)
Section cross-reference(s): **17**
IT 56-85-9, L-Glutamine, biological studies 56-86-0, L-Glutamic acid, biological studies 57-00-1, Creatine 60-18-4, Tyrosine, biological studies 62-49-7, Choline 73-22-3, Tryptophan, biological studies 74-79-3, L-Arginine, biological studies 107-43-7, Betaine 541-15-1, Carnitine **625-08-1**, β-Hydroxy-β-methylbutyric acid 1406-16-2, Vitamin D 1406-18-4, Vitamin E 3416-24-8, Glucosamine 7440-66-6D, Zinc, complexes 11103-57-4, Vitamin A 29908-03-0 **135236-72-5**
RL: **FFD (Food or feed use)**; BIOL (Biological study); **USES (Uses)**
(oviparous species development by in ovo feeding of enteric modulators)

L38 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:964935 CAPLUS
DOCUMENT NUMBER: 138:29176
TITLE: Appetite suppressant composition comprising a chromium additive, and green tea leaf extract
INVENTOR(S): Mamana, John
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002192308	A1	20021219	US 2001-880084	20010614
PRIORITY APPLN. INFO.:			US 2001-880084	20010614

ED Entered STN: 20 Dec 2002
AB An appetite suppressant and a method for controlling the weight of a person is described. The appetite suppressant is a composition that includes a chromium additive, green tea, and green tea leaf extract containing catechin polyphenols. The method for controlling the weight of a person includes replacing at least one meal per day with a soy meal replacement and taking an appetite suppressant that contains a chromium additive, green tea, and green tea leaf extract Also described is a weight control kit that includes a soy meal replacement and an appetite suppressant that contains a chromium additive, green tea, and green tea leaf extract
IC ICM A61K035-78
ICS A61K033-24; A61K031-555; A61K031-404
INCL 424729000; 424760000; 424655000; 514184000; 514419000
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 1
IT 98-98-6, 2-Pyridinecarboxylic acid **625-08-1** 4350-09-8, 5-Hydroxytryptophan 7440-47-3D, Chromium, polynicotinate complexes 16887-00-6, Chloride, biological studies

RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(appetite suppressant composition comprising chromium additive, and green tea leaf extract)

L38 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:905843 CAPLUS
DOCUMENT NUMBER: 137:389186
TITLE: Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
INVENTOR(S): Heyl-Frank, Brigitta; Irle, Heike; Pianzola, Daniel; Zacher, Uwe; Jackson, Barry
PATENT ASSIGNEE(S): Lonza A.-G., Switz.
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094255	A1	20021128	WO 2002-EP5435	20020517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2447417	AA	20021128	CA 2002-2447417	20020517
EP 1399138	A1	20040324	EP 2002-743039	20020517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009820	A	20040601	BR 2002-9820	20020517
CN 1523983	A	20040825	CN 2002-813599	20020517
JP 2004536065	T2	20041202	JP 2002-590973	20020517
US 2004143136	A1	20040722	US 2003-478054	20031118
PRIORITY APPLN. INFO.:			EP 2001-112236 A	20010518
			WO 2002-EP5435 W	20020517

ED Entered STN: 29 Nov 2002
AB Solid formulations of sodium 3-hydroxy-3-methylbutyrate are produced by the hydrolysis of 4,4-dimethyl-2-oxetanone with aqueous sodium hydroxide to give a solution of sodium 3-hydroxy-3-methylbutyrate and the obtained solution is absorbed onto synthetic silicic acid. The formulations are lightly hygroscopic and easily handled. The product is recommended for veterinary drug and as feed supplement.
IC ICM A61K031-19
CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 18
IT **155206-13-6P**
RL: SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); **USES (Uses)**
(method for production of solid formulations of sodium 3-hydroxy-3-methylbutyrate)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:749446 CAPLUS
DOCUMENT NUMBER: 133:286430
TITLE: Pyruvic acid water-soluble and stable formulations
INVENTOR(S): Seyerl, Joachim V.
PATENT ASSIGNEE(S): SKW Trostberg A.-G., Germany
SOURCE: Brit. UK Pat. Appl., 13 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2345247	A1	20000705	GB 1999-30094	19991220
DE 19859771	C1	20000824	DE 1998-19859771	19981223
PRIORITY APPLN. INFO.:			DE 1998-19859771 A	19981223

ED Entered STN: 25 Oct 2000
AB A water-soluble, stable formulation containing pyruvic acid or its salt comprise
(a) at least one saccharide or its derivative and/or one or more physiol. acceptable salts thereof, and p (b) pyruvic acid or at least one salt thereof which is different from component (a), or mixture thereof. In addition, the formulation can contain up to 20% of an alkaline earth metal carbonate and/or of an alkaline earth metal salt of an organic carboxylic acid such a as citric acid or ascorbic acid, up to 20% of other physiol. active substances such as sugar, vitamins, trace elements etc., and/or up to 20% of formulation aids. The proposed formulation is advantageous especially for the prevention and treatment of dystrophic and/or degenerative and/or inflammatory arthropathies. A pharmaceutical powder contained glucosamine 500, calcium pyruvate 750, magnesium hydrogen-L-aspartate 720, glucose 2000, and ascorbic acid 500 mg.
IC ICM A61K031-70
ICA A61K031-19; A61P003-02
CC **63-6** (Pharmaceuticals)
IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 56-41-7, Alanine, biological studies 56-84-8, Aspartic acid, biological studies 56-85-9, Glutamine, biological studies 57-00-1, Creatine 57-11-4D, Octadecanoic acid, salts, biological studies 70-26-8, Ornithine 74-79-3, Arginine, biological studies 77-92-9, Citric acid, biological studies 127-17-3, Pyruvic acid, biological studies 127-17-3D, Pyruvic acid, salts 131-48-6, N-Acetylneuraminic acid 328-50-7 526-95-4, Gluconic acid 541-15-1, Carnitine **625-08-1** 1200-22-2, α-Lipoic acid 3416-24-8, Glucosamine 7439-89-6, Iron, biological studies 7439-98-7, Molybdenum, biological studies 7440-42-8, Boron, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7631-86-9, Silica, biological studies 7782-49-2, Selenium, biological studies 9003-39-8, Polyvinyl pyrrolidone 9004-61-9, Hyaluronic acid 9004-67-5, Methyl cellulose 9007-27-6, Chondroitin 27750-10-3, Hydroxycitric acid 29261-87-8, Glucosamine pyruvate
RL: **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(pyruvic acid water-soluble and stable formulations)

L38 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:513519 CAPLUS
DOCUMENT NUMBER: 133:115087

TITLE: Composition of anti-HIV drugs and anti-cortisol compounds, and method for decreasing the side effects of anti-HIV drugs in a human
INVENTOR(S): Sapse, Alfred T.
PATENT ASSIGNEE(S): Steroidogenesis Inhibitors International, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000043017	A1	20000727	WO 2000-US1364	20000120
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2005085464	A1	20050421	US 2004-918737	20040816
PRIORITY APPLN. INFO.:			US 1999-234532 A	19990121

ED Entered STN: 28 Jul 2000
AB The invention is based, in part, on the discovery that the use of an anti-HIV drug in combination with at least one cortisol blocker, e.g. procaine, reduces the side effects associated with anti-HIV drugs. The invention also relates to a method of treating the high cortisol catabolic effects of diseases such as AIDS in the HIV pos. population and those with AIDS-related complexes by the administration of a cortisol blocker. The invention also discloses a composition comprising an anti-HIV drug and a cortisol blocker. More specifically, the invention relates to a cortisol-blocking composition which comprises procaine, ascorbic acid and zinc heptahydrate.
IC ICM A61K031-70
CC 1-5 (Pharmacology)
Section cross-reference(s): 2, **63**
IT 50-81-7, Ascorbic acid, biological studies 51-05-8, Procaine hydrochloride 53-43-0, DHEA 57-41-0, Phenytoin 73-78-9, Lidocaine hydrochloride 145-13-1, Pregnenolone **625-08-1** 4205-90-7, Clonidine 7440-66-6, Zinc, biological studies 7440-66-6D, Zinc, salts and hydrates, biological studies 35212-22-7, Ipriflavone 65277-42-1, Ketoconazole 84371-65-3, RU-486
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(anti-HIV drug and anti-cortisol compound composition, and method for decreasing the side effects of anti-HIV drugs in a human)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:98317 CAPLUS
DOCUMENT NUMBER: 128:172123
TITLE: Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal

INVENTOR(S): Beale, Paxton K.
PATENT ASSIGNEE(S): Beale, Paxton K., USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804253	A1	19980205	WO 1997-US13161	19970725
W: AT, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, LU, MX, PL, PT, RO, RU, SE, SK, UA				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5756469	A	19980526	US 1996-686820	19960726
CA 2261781	AA	19980205	CA 1997-2261781	19970725
EP 914108	A1	19990512	EP 1997-935137	19970725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9710585	A	20001024	BR 1997-10585	19970725
US 5919767	A	19990706	US 1998-27522	19980223
PRIORITY APPLN. INFO.:			US 1996-686820 A	19960726
			WO 1997-US13161 W	19970725

ED Entered STN: 19 Feb 1998

AB The present invention is based, in part, upon the discovery that the use of pyruvate in combination with a cortisol blocker, such as phosphatidylserine, produces a synergistic effect in increasing lean body mass or muscle tissue, decreasing fat deposition, increasing endurance and athletic performance of a mammal consuming same. The invention also relates to a method of treating the catabolic effects of diseases such as cancer and AIDS by the administration of pyruvate and a cortisol blocker. The present invention also discloses a synergistic composition comprising pyruvate and a cortisol blocker. More specifically, the present invention relates to a composition which comprises pyruvate and/or derivs. of pyruvate and phosphatidylserine.

IC ICM A61K031-19
ICS A61K031-66; A61K045-06

CC **63-6** (Pharmaceuticals)
Section cross-reference(s): 18

IT 53-43-0, DHEA 56-86-0, Glutamic acid, biological studies 61-90-5, Leucine, biological studies 113-24-6, Sodium pyruvate 145-13-1, Pregnenolone **625-08-1** 631-66-3, Pyruvamide 1839-11-8, Conjugated linoleic acid 2392-63-4 3997-91-9, Pyruvoyl glycine 4151-33-1, Potassium pyruvate 6020-87-7, Creatine monohydrate 16947-06-1 18983-79-4, Magnesium pyruvate 35212-22-7, Ipriflavone 52009-14-0, Calcium pyruvate 68259-69-8 76391-12-3 90088-56-5 152102-61-9 155404-03-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); **USES (Uses)**
(enteral synergistic compns. containing pyruvates and cortisol blockers for enhancing muscle mass)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:183862 CAPLUS
DOCUMENT NUMBER: 102:183862
TITLE: Decolorization and degradation products of melanoidins

on ozonolysis
AUTHOR(S): Kim, Seon Bong; Hayase, Fumitaka; Kato, Hiromichi
CORPORATE SOURCE: Dep. Agric. Chem., Univ. Tokyo, Tokyo, 113, Japan
SOURCE: Agricultural and Biological Chemistry (1985), 49(3), 785-92
CODEN: ABCHA6; ISSN: 0002-1369
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 02 Jun 1985
AB Nondialyzable melanoidins prepared from a glucose [50-99-7]-glycine [56-40-6] system were investigated as to their decolorization and degradation products on O3 treatment. Melanoidins were decolorized to degrees of 84 and 97% after ozonolysis at -1° for 10 min and 90 min, resp., and the mean mol. weight of melanoidins decreased from 7000 to 3000 after ozonolysis for 40 min. The major components of electrofocused melanoidins before and after ozone treatment had isoelec. points (pI) of 3.00 and 2.86, resp., the pI 3.00 band being significantly affected. IR measurement showed that the absorbance at 1290 cm-1 disappeared, and that at 1720 cm-1 newly appeared, on ozonolysis, and the absorption at 1620 cm-1 disappeared on acid hydrolysis after ozonolysis. Further, the major degradation products in the ether-soluble fractions obtained from ozone-treated melanoidins were identified as butanedioic acid [110-15-6], glycolic acid [79-14-1], 2-hydroxybutanoic acid [565-70-8], etc. In the aqueous fraction, 1 of the major products was glycine, which was produced to the level of 1.05% on ozonolysis and increased to 5.75% of melanoidin on acid hydrolysis after ozonolysis. From these findings and the IR results, it is postulated that glycine was considerably incorporated into melanoidin mols. as the amide form.
CC **17-2** (Food and Feed Chemistry)
IT 79-14-1, uses and miscellaneous 110-15-6, uses and miscellaneous 141-82-2, biological studies 144-62-7, biological studies 516-05-2 594-61-6 600-15-7 **625-08-1** 625-45-6
RL: **USES (Uses)**
(degradation product, from ozone-treated melanoidin)

=> □

=> fil medline
FILE 'MEDLINE' ENTERED AT 10:23:29 ON 30 JAN 2006

FILE LAST UPDATED: 28 JAN 2006 (20060128/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 will soon be available. For details on the 2005 reload, enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate

```
=> d his ful

     (FILE 'REGISTRY' ENTERED AT 09:45:52 ON 30 JAN 2006)
                DEL HIS Y
                ACT MITCH/A
               ---------
L1               STR
L2            37 SEA FAM FUL L1
               ---------
L3             2 SEA ABB=ON  PLU=ON  L2 AND CA/ELS
L4             1 SEA ABB=ON  PLU=ON  L2 AND MG/ELS
L5             1 SEA ABB=ON  PLU=ON  L2 AND 625-08-1

     FILE 'CAPLUS' ENTERED AT 09:49:28 ON 30 JAN 2006
L6            17 SEA ABB=ON  PLU=ON  L3 OR L4
L7             4 SEA ABB=ON  PLU=ON  L6 AND (PHARMACEUT?/OBI OR 63/SX,SC)
                 D SCAN
L8             2 SEA ABB=ON  PLU=ON  L6 AND PARENTER?/BI
L9        145270 SEA ABB=ON  PLU=ON  DRUG DELIVER?/OBI
L10            4 SEA ABB=ON  PLU=ON  L9 AND L6
L11            6 SEA ABB=ON  PLU=ON  L7 OR L8 OR L10

     FILE 'REGISTRY' ENTERED AT 09:53:11 ON 30 JAN 2006
                E CALCIUM/CN
L12            1 SEA ABB=ON  PLU=ON  CALCIUM/CN
                E CALCIUM ION/CN
L13            1 SEA ABB=ON  PLU=ON  "CALCIUM ION"/CN
                E MAGNESIUM/CN
L14            1 SEA ABB=ON  PLU=ON  MAGNESIUM/CN
                E MAGNESIUM ION/CN
L15            1 SEA ABB=ON  PLU=ON  "MAGNESIUM ION"/CN

     FILE 'CAPLUS' ENTERED AT 09:53:49 ON 30 JAN 2006

L16       374965 SEA ABB=ON  PLU=ON  L12 OR L13
L17       218071 SEA ABB=ON  PLU=ON  L14 OR L15
L18          317 SEA ABB=ON  PLU=ON  L5
L19           12 SEA ABB=ON  PLU=ON  L18 AND L16
L20           11 SEA ABB=ON  PLU=ON  L18 AND L17
L21           14 SEA ABB=ON  PLU=ON  (L19 OR L20)
L22           10 SEA ABB=ON  PLU=ON  L21 AND ((PARENTER? OR PHARMACEU?)/BI OR
                 L9 OR 63/SX,SC)
L23           15 SEA ABB=ON  PLU=ON  L22 OR L11
                 D TI 1-10
L24         4374 SEA ABB=ON  PLU=ON  (HYPOCALCEMIA OR HYPOMAGNESIA OR HYPERKALEM
                 IA)/BI
L25            1 SEA ABB=ON  PLU=ON  L24 AND L18
L26            1 SEA ABB=ON  PLU=ON  L24 AND L6
L27            1 SEA ABB=ON  PLU=ON  L25 OR L26
                 D SCAN
L28           15 SEA ABB=ON  PLU=ON  L27 OR L23
L29           36 SEA ABB=ON  PLU=ON  DOBBINS T?/AU
L30          353 SEA ABB=ON  PLU=ON  WILEY D?/AU
L31         3592 SEA ABB=ON  PLU=ON  DAVIS M?/AU
L32         3974 SEA ABB=ON  PLU=ON  (L29 OR L30 OR L31)
L33          347 SEA ABB=ON  PLU=ON  L2
L34            3 SEA ABB=ON  PLU=ON  L33 AND L32
                 D SCAN
L35           71 SEA ABB=ON  PLU=ON  L33 (L) (FFD OR THU OR USES)/RL
```

```
L36          41 SEA ABB=ON  PLU=ON  L35 AND (63 OR 18 OR 17)/SC,SX
L37          21 SEA ABB=ON  PLU=ON  L35 AND (63 OR 17)/SC,SX
L38          10 SEA ABB=ON  PLU=ON  L37 NOT L28
                D SCAN TI
L39           0 SEA ABB=ON  PLU=ON  L34 NOT L28

L40          84 SEA ABB=ON  PLU=ON  L32 AND L16
L41          37 SEA ABB=ON  PLU=ON  L32 AND L17
L42         101 SEA ABB=ON  PLU=ON  L40 OR L41
L43           1 SEA ABB=ON  PLU=ON  L42 AND L24
                D L28 .CA 1-15
                D .CA L38 1-10
                D COST

     FILE 'MEDLINE' ENTERED AT 10:07:18 ON 30 JAN 2006
L44         110 SEA ABB=ON  PLU=ON  L2
                E VALERATES/CT
                E E3+AL
                E E3+ALL
                E CALCIUM/CT
                E E3+NT
                E MAGNESIUM/CT
                E E3+ALL
L45        2221 SEA ABB=ON  PLU=ON  VALERATES/CT OR PENTANOIC ACIDS/CT
L46        1052 SEA ABB=ON  PLU=ON  L44 OR L45/MAJ
                E CALCIUM COMPOUNDS/CT
                E E3+ALL
                E MAGNESIUM COMPOUNDS/CT
                E E3+ALL
L47        2184 SEA ABB=ON  PLU=ON  CALCIUM COMPOUNDS/CT OR MAGNESIUM COMPOUNDS
                /CT
L48           1 SEA ABB=ON  PLU=ON  L46 AND L47
                D TRIAL
                E HYPOCALCEMIA/CT
                E E3+ALL
L49        5942 SEA ABB=ON  PLU=ON  HYPOCALCEMIA+NT/CT
                E HYPOMAGNESIUM/CT
L50           1 SEA ABB=ON  PLU=ON  L49 AND L46
                D TRIAL
L51         455 SEA ABB=ON  PLU=ON  L45 (L) TU./CT
                E CALCIUM/CT
L52      187601 SEA ABB=ON  PLU=ON  CALCIUM/CT
L53       51418 SEA ABB=ON  PLU=ON  MAGNESIUM/CT
L54           2 SEA ABB=ON  PLU=ON  L51 AND (L52 OR L53 OR L47)
                D TRIAL
L55           5 SEA ABB=ON  PLU=ON  L44 AND (L52 OR L53 OR L47)
L56           6 SEA ABB=ON  PLU=ON  L55 OR L54 OR L50 OR L48
                D TI 1-67
                E DOBBINS T/AU
L57          14 SEA ABB=ON  PLU=ON  ("DOBBINS T"/AU OR "DOBBINS T A"/AU OR
                "DOBBINS T E"/AU OR "DOBBINS T W"/AU OR "DOBBINS THOMAS"/AU OR
                "DOBBINS THOMAS A"/AU)
                E WILEY D/AU
L58          16 SEA ABB=ON  PLU=ON  "WILEY D"/AU OR "WILEY D B"/AU
                E WILEY DAVID/AU
L59           6 SEA ABB=ON  PLU=ON  ("WILEY DAVID C"/AU OR "WILEY DAVID F"/AU
                OR "WILEY DAVID J"/AU)
                E DAVIS M/AU
L60        2630 SEA ABB=ON  PLU=ON  ("DAVIS M"/AU OR "DAVIS M A"/AU OR "DAVIS
                M B"/AU OR "DAVIS M B JR"/AU OR "DAVIS M C"/AU OR "DAVIS M
```

```
                D"/AU OR "DAVIS M D P"/AU OR "DAVIS M DUFF"/AU OR "DAVIS M
                E"/AU OR "DAVIS M E JR"/AU OR "DAVIS M F"/AU OR "DAVIS M G"/AU
                OR "DAVIS M G JR"/AU OR "DAVIS M H"/AU OR "DAVIS M H JR"/AU OR
                "DAVIS M I"/AU OR "DAVIS M J"/AU OR "DAVIS M JR"/AU OR "DAVIS
                M K"/AU OR "DAVIS M L"/AU OR "DAVIS M M"/AU OR "DAVIS M M
                D"/AU OR "DAVIS M N"/AU OR "DAVIS M O"/AU OR "DAVIS M P"/AU OR
                "DAVIS M R"/AU OR "DAVIS M S"/AU OR "DAVIS M S JR"/AU OR
                "DAVIS M T"/AU OR "DAVIS M V"/AU OR "DAVIS M W"/AU OR "DAVIS M
                W L"/AU OR "DAVIS M WAYNE"/AU OR "DAVIS M Z"/AU)
                E DAVIS MICHAEL/AU
L61          138 SEA ABB=ON  PLU=ON  ("DAVIS MICHAEL"/AU OR "DAVIS MICHAEL
                A"/AU OR "DAVIS MICHAEL C"/AU OR "DAVIS MICHAEL D"/AU OR
                "DAVIS MICHAEL E"/AU OR "DAVIS MICHAEL F"/AU OR "DAVIS MICHAEL
                G"/AU OR "DAVIS MICHAEL H"/AU OR "DAVIS MICHAEL J"/AU OR
                "DAVIS MICHAEL M"/AU OR "DAVIS MICHAEL R"/AU OR "DAVIS MICHAEL
                S"/AU OR "DAVIS MICHAEL SEAN"/AU OR "DAVIS MICHAEL T"/AU OR
                "DAVIS MICHAEL W"/AU)
L62         2804 SEA ABB=ON  PLU=ON  (L57 OR L58 OR L59 OR L60 OR L61)
L63            0 SEA ABB=ON  PLU=ON  L62 AND (L44 OR L45)
L64           53 SEA ABB=ON  PLU=ON  L62 AND (L47 OR L52 OR L53)
L65            1 SEA ABB=ON  PLU=ON  L64 AND TH./CT
                D TRIAL
                E HYPOCALCEMIA/CT
L66         5942 SEA ABB=ON  PLU=ON  HYPOCALCEMIA+NT/CT
L67            0 SEA ABB=ON  PLU=ON  L66 AND L62
L68            1 SEA ABB=ON  PLU=ON  L67 OR L65 OR L63
                E DRUG DELIVERY/CT
                E E5+NT/CT
L69        92903 SEA ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+NT/CT
L70           27 SEA ABB=ON  PLU=ON  L69 AND L62
L71            0 SEA ABB=ON  PLU=ON  L70 AND L64
L72            1 SEA ABB=ON  PLU=ON  L68 OR L71
```

```
=> d que nos l56
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L44         110 SEA FILE=MEDLINE ABB=ON  PLU=ON  L2
L45        2221 SEA FILE=MEDLINE ABB=ON  PLU=ON  VALERATES/CT OR PENTANOIC
                ACIDS/CT
L46        1052 SEA FILE=MEDLINE ABB=ON  PLU=ON  L44 OR L45/MAJ
L47        2184 SEA FILE=MEDLINE ABB=ON  PLU=ON  CALCIUM COMPOUNDS/CT OR
                MAGNESIUM COMPOUNDS/CT
L48           1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L46 AND L47
L49        5942 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYPOCALCEMIA+NT/CT
L50           1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L49 AND L46
L51         455 SEA FILE=MEDLINE ABB=ON  PLU=ON  L45 (L) TU./CT
L52      187601 SEA FILE=MEDLINE ABB=ON  PLU=ON  CALCIUM/CT
L53       51418 SEA FILE=MEDLINE ABB=ON  PLU=ON  MAGNESIUM/CT
L54           2 SEA FILE=MEDLINE ABB=ON  PLU=ON  L51 AND (L52 OR L53 OR L47)
L55           5 SEA FILE=MEDLINE ABB=ON  PLU=ON  L44 AND (L52 OR L53 OR L47)
L56           6 SEA FILE=MEDLINE ABB=ON  PLU=ON  L55 OR L54 OR L50 OR L48


=> d que nos l72
L1              STR
L2           37 SEA FILE=REGISTRY FAM FUL L1
L44         110 SEA FILE=MEDLINE ABB=ON  PLU=ON  L2
L45        2221 SEA FILE=MEDLINE ABB=ON  PLU=ON  VALERATES/CT OR PENTANOIC
                ACIDS/CT
L47        2184 SEA FILE=MEDLINE ABB=ON  PLU=ON  CALCIUM COMPOUNDS/CT OR
                MAGNESIUM COMPOUNDS/CT
L52      187601 SEA FILE=MEDLINE ABB=ON  PLU=ON  CALCIUM/CT
L53       51418 SEA FILE=MEDLINE ABB=ON  PLU=ON  MAGNESIUM/CT
L57          14 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("DOBBINS T"/AU OR "DOBBINS T
                A"/AU OR "DOBBINS T E"/AU OR "DOBBINS T W"/AU OR "DOBBINS
                THOMAS"/AU OR "DOBBINS THOMAS A"/AU)
L58          16 SEA FILE=MEDLINE ABB=ON  PLU=ON  "WILEY D"/AU OR "WILEY D
                B"/AU
L59           6 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("WILEY DAVID C"/AU OR "WILEY
                DAVID F"/AU OR "WILEY DAVID J"/AU)
L60        2630 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("DAVIS M"/AU OR "DAVIS M
                A"/AU OR "DAVIS M B"/AU OR "DAVIS M B JR"/AU OR "DAVIS M C"/AU
                OR "DAVIS M D"/AU OR "DAVIS M D P"/AU OR "DAVIS M DUFF"/AU OR
                "DAVIS M E"/AU OR "DAVIS M E JR"/AU OR "DAVIS M F"/AU OR
                "DAVIS M G"/AU OR "DAVIS M G JR"/AU OR "DAVIS M H"/AU OR
                "DAVIS M H JR"/AU OR "DAVIS M I"/AU OR "DAVIS M J"/AU OR
                "DAVIS M JR"/AU OR "DAVIS M K"/AU OR "DAVIS M L"/AU OR "DAVIS
                M M"/AU OR "DAVIS M M D"/AU OR "DAVIS M N"/AU OR "DAVIS M
                O"/AU OR "DAVIS M P"/AU OR "DAVIS M R"/AU OR "DAVIS M S"/AU OR
                "DAVIS M S JR"/AU OR "DAVIS M T"/AU OR "DAVIS M V"/AU OR
                "DAVIS M W"/AU OR "DAVIS M W L"/AU OR "DAVIS M WAYNE"/AU OR
                "DAVIS M Z"/AU)
L61         138 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("DAVIS MICHAEL"/AU OR "DAVIS
                MICHAEL A"/AU OR "DAVIS MICHAEL C"/AU OR "DAVIS MICHAEL D"/AU
                OR "DAVIS MICHAEL E"/AU OR "DAVIS MICHAEL F"/AU OR "DAVIS
                MICHAEL G"/AU OR "DAVIS MICHAEL H"/AU OR "DAVIS MICHAEL J"/AU
                OR "DAVIS MICHAEL M"/AU OR "DAVIS MICHAEL R"/AU OR "DAVIS
                MICHAEL S"/AU OR "DAVIS MICHAEL SEAN"/AU OR "DAVIS MICHAEL
                T"/AU OR "DAVIS MICHAEL W"/AU)
L62        2804 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L57 OR L58 OR L59 OR L60 OR
                L61)
```

```
L63            0 SEA FILE=MEDLINE ABB=ON  PLU=ON  L62 AND (L44 OR L45)
L64           53 SEA FILE=MEDLINE ABB=ON  PLU=ON  L62 AND (L47 OR L52 OR L53)
L65            1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L64 AND TH./CT
L66         5942 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYPOCALCEMIA+NT/CT
L67            0 SEA FILE=MEDLINE ABB=ON  PLU=ON  L66 AND L62
L68            1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L67 OR L65 OR L63
L69        92903 SEA FILE=MEDLINE ABB=ON  PLU=ON  DRUG DELIVERY SYSTEMS+NT/CT
L70           27 SEA FILE=MEDLINE ABB=ON  PLU=ON  L69 AND L62
L71            0 SEA FILE=MEDLINE ABB=ON  PLU=ON  L70 AND L64
L72            1 SEA FILE=MEDLINE ABB=ON  PLU=ON  L68 OR L71


=> d ibib ab ct l56 1-6;d ibib ab ct l62 1

L56  ANSWER 1 OF 6     MEDLINE on STN
ACCESSION NUMBER:    2005510196     MEDLINE
DOCUMENT NUMBER:     PubMed ID: 16006030
TITLE:               Dietary toxicity of calcium beta-hydroxy-beta-methyl
                     butyrate (CaHMB).
AUTHOR:              Baxter J H; Carlos J L; Thurmond J; Rehani R N; Bultman J;
                     Frost D
CORPORATE SOURCE:    Ross Products Division, Department 104060 RP43, Abbott
                     Laboratories, Columbus, OH 43215-1724, USA..
                     jeffrey.baxter@abbott.com
SOURCE:              Food and chemical toxicology : an international journal
                     published for the British Industrial Biological Research
                     Association, (2005 Dec) 43 (12) 1731-41.
                     Journal code: 8207483. ISSN: 0278-6915.
PUB. COUNTRY:        England: United Kingdom
DOCUMENT TYPE:       Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:            English
FILE SEGMENT:        Priority Journals
ENTRY MONTH:         200512
ENTRY DATE:          Entered STN: 20050927
                     Last Updated on STN: 20051230
                     Entered Medline: 20051229
AB   HMB, 3-hydroxy-3-methyl butyrate, is of interest as a dietary supplement
     and a possible component of functional and medical foods. The purpose of
     this study was to evaluate the toxicity of the calcium salt of HMB,
     calcium 3-hydroxy-3-methyl butyrate (CaHMB, monohydrate, food grade), when
     administered daily in the diet of rats for at least 90 days. Male and
     female Crl:CD (SD)IGS BR animals were assigned to four groups. Each group
     received diets containing the carrier or 1%, 2%, or 5% of CaHMB mixed with
     diet. Assessment of toxicity was based on mortality, clinical
     observations, body weights, food consumption, and clinical and anatomic
     pathology evaluations. Administration of CaHMB in basal diet for 91 days
     was tolerated well. There were no unscheduled sacrifices or deaths.
     There were no CaHMB-related adverse effects on clinical observations, body
     weights, food consumption, clinical chemistry, hematology, absolute or
     relative organ weights, or macroscopic or microscopic observations. A
     statistically significant increase in inorganic phosphorous was observed
     in male animals in the 5% feeding group; however, this effect was not
     considered adverse. Based on the results of this study, the
     no-observed-adverse-effect level (NOAEL) was considered to be 5% of CaHMB
     mixed with diet (3.49 g/kg BW for males and 4.16 g/kg BW for females).
CT   Check Tags: Female; Male
      Administration, Oral
      Animals
      Body Weight: DE, drug effects
        Calcium Compounds: PK, pharmacokinetics
```

***Calcium Compounds: TO, toxicity**
Dose-Response Relationship, Drug
Eating: DE, drug effects
No-Observed-Adverse-Effect Level
Organ Size: DE, drug effects
Organ Specificity: DE, drug effects
Random Allocation
Rats
Research Support, Non-U.S. Gov't
Sex Factors
Toxicity Tests, Chronic
Valerates: PK, pharmacokinetics
***Valerates: TO, toxicity**

L56 ANSWER 2 OF 6 MEDLINE on STN
ACCESSION NUMBER: 2003303925 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12831686
TITLE: Supplement use in the adolescent athlete.
AUTHOR: DesJardins Matt
CORPORATE SOURCE: The University of Utah, The Orthopedic Specialty Hospital, 5848 South 300 East, Salt Lake City, UT 84107, USA.. mtdmd@hotmail.com
SOURCE: Current sports medicine reports, (2002 Dec) 1 (6) 369-73. Ref: 58
Journal code: 101134380. ISSN: 1537-890X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200601
ENTRY DATE: Entered STN: 20030701
Last Updated on STN: 20031218
Entered Medline: 20060103

AB Use of dietary supplements has become common practice among adolescent athletes in the United States. Concern has arisen regarding safety in adolescents in light of the fact that supplements are not required to meet usual US Food and Drug Administration requirements for standard pharmaceuticals. Furthermore, advertised ergogenic gains are based on little or no scientific evidence. Creatine, anabolic steroids, androstenedione, dehydroepiandrosterone, caffeine, ephedrine-type alkaloids, calcium beta-hydroxy-beta-methybutyrate, and human growth hormone are reviewed. Although some studies have indicated performance benefit in particular athletic situations, there are few available data in adolescents. Furthermore, the few safety studies of these supplements do not include adolescents. Adolescents may be at particular risk when using anabolic steroids and caffeine-ephedra combinations. Research has demonstrated effective education programs can reduce adolescents' intentions to use dietary supplements.

CT Adolescent
Adrenergic Agents: AD, administration & dosage
Adrenergic Agents: AE, adverse effects
Alkaloids: AD, administration & dosage
Alkaloids: AE, adverse effects
Anabolic Agents: AD, administration & dosage
Anabolic Agents: AE, adverse effects
Caffeine: AD, administration & dosage
Caffeine: AE, adverse effects
Calcium: AD, administration & dosage
Calcium: AE, adverse effects

Central Nervous System Stimulants: AD, administration & dosage
Central Nervous System Stimulants: AE, adverse effects
Creatine: AD, administration & dosage
Creatine: AE, adverse effects
*Dietary Supplements: AE, adverse effects
*Doping in Sports
Ephedrine: AD, administration & dosage
Ephedrine: AE, adverse effects
Human Growth Hormone: AD, administration & dosage
Human Growth Hormone: AE, adverse effects
Humans
Valerates: AD, administration & dosage
Valerates: AE, adverse effects

L56 ANSWER 3 OF 6 MEDLINE on STN
ACCESSION NUMBER: 2002674829 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12435662
TITLE: When food becomes a drug: nonanabolic nutritional supplement use in athletes.
AUTHOR: Schwenk Thomas L; Costley Chad D
CORPORATE SOURCE: Department of Family Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109, USA.
SOURCE: American journal of sports medicine, (2002 Nov-Dec) 30 (6) 907-16. Ref: 51
Journal code: 7609541. ISSN: 0363-5465.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20021119
Last Updated on STN: 20030306
Entered Medline: 20030305

AB The use of nonanabolic nutritional supplements for the sake of improving athletic performance is common, and the types of supplements used can have significant implications for the medical care of athletes. This review will address the most common and most controversial nonanabolic nutritional supplements, including recommendations regarding their use. Many supplements are marketed and promoted based on various theoretical benefits, often derived from limited animal studies, without any basis for recommending their human use. Physicians are trained to not recommend a nutritional supplement unless it is known to be effective, whereas athletes are oriented toward trying any supplement or ergogenic aid as long as it is safe, with the hope that it may be effective. The built-in error in most study designs is larger than the difference between winning and not qualifying at elite levels of competition, such that research may not always answer the questions raised by athletes. An honest discussion of the limitations of most supplements, and acknowledgment that some supplements may work some of the time in some athletes, may lead the physician to be more credible and useful to athletes in providing medical care and guidance that support their desire to improve their performance.

CT Amino Acids, Branched-Chain: PD, pharmacology
Ascorbic Acid: PD, pharmacology
Caffeine
Calcium: PD, pharmacology
Chondroitin Sulfates: PD, pharmacology
Chromium: PD, pharmacology
Copper: PD, pharmacology

Creatinine: PD, pharmacology
Dehydroepiandrosterone: PD, pharmacology
*Dietary Supplements
Exercise: PH, physiology
Food, Fortified
Gelatin: PD, pharmacology
Glucosamine: PD, pharmacology
Humans
Iron, Dietary: PD, pharmacology
Magnesium: PD, pharmacology
Nutrition Policy
Panax
Selenium: PD, pharmacology
*Sports
Sports: PH, physiology
Task Performance and Analysis
Valerates: PD, pharmacology
Vitamin B Complex: PD, pharmacology
Vitamin E: PD, pharmacology
Zinc: PD, pharmacology

L56 ANSWER 4 OF 6 MEDLINE on STN
ACCESSION NUMBER: 2000072228 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10606212
TITLE: Effects of calcium beta-hydroxy-beta-methylbutyrate (HMB) supplementation during resistance-training on markers of catabolism, body composition and strength.
AUTHOR: Kreider R B; Ferreira M; Wilson M; Almada A L
CORPORATE SOURCE: Department of Human Movement Sciences & Education, The University of Memphis, TN 38152, USA.. kreider.richard@coe.memphis.edu
SOURCE: International journal of sports medicine, (1999 Nov) 20 (8) 503-9.
Journal code: 8008349. ISSN: 0172-4622.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200001
ENTRY DATE: Entered STN: 20000114
Last Updated on STN: 20000114
Entered Medline: 20000104

AB Calcium beta-hydroxy-beta-methylbutyrate (HMB) supplementation has been reported to reduce muscle catabolism and promote gains in fat-free mass and strength in subjects initiating training. However, whether HMB supplementation promotes these adaptations in trained athletes is less clear. This study examined the effects of HMB (as the calcium salt) supplementation during resistance training (6.9+/-0.7 hr x wk(-1)) on markers of catabolism, body composition and strength in experienced resistance-trained males. In a double-blind and randomized manner, 40 experienced resistance-trained athletes were matched and assigned to supplement their diet for 28 d with a fortified carbohydrate/protein powder containing either 0, 3 or 6 g x d(-1) of calcium HMB. Fasting venous blood and urine samples, dual energy X-ray absorptiometer-determined body composition, and isotonic bench press and leg press one repetition maximums (1 RM) were determined prior to and following 28 d of supplementation. HMB supplementation resulted in significant increases in serum and urinary HMB concentrations. However, no statistically

significant differences were observed in general markers of whole body anabolic/catabolic status, muscle and liver enzyme efflux, fat/bone-free mass, fat mass, percent body fat, or 1 RM strength. Results indicate that 28 d of HMB supplementation (3 to 6 g x d(-1)) during resistance-training does not reduce catabolism or affect training-induced changes in body composition and strength in experienced resistance-trained males.

CT Check Tags: Male
Adult
Analysis of Variance
Biological Markers
*Body Composition: PH, physiology
Calcium: AD, administration & dosage
*Dietary Supplements
*Energy Metabolism: PH, physiology
Humans
Liver: EN, enzymology
Muscle, Skeletal: EN, enzymology
*Muscle, Skeletal: PH, physiology
*Physical Education and Training: MT, methods
Questionnaires
Research Support, Non-U.S. Gov't
***Valerates: AD, administration & dosage**

L56 ANSWER 5 OF 6 MEDLINE on STN
ACCESSION NUMBER: 97005174 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8852485
TITLE: Calcium beta-hydroxy-beta-methylbutyrate. 1. Potential role as a phosphate binder in uremia: in vitro study.
AUTHOR: Sousa M F; Abumrad N N; Martins C; Nissen S; Riella M C
CORPORATE SOURCE: Department of Medicine, Evangelic School of Medicine, Curitiba, Brazil.
SOURCE: Nephron, (1996) 72 (3) 391-4.
Journal code: 0331777. ISSN: 0028-2766.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199612
ENTRY DATE: Entered STN: 19970128
Last Updated on STN: 19970128
Entered Medline: 19961211

AB The binding capacity of calcium beta-hydroxy-beta-methylbutyrate (calcium HMB), compared to other binders, was investigated in an in vitro study. Fifty milliequivalents of either calcium HMB, calcium acetate, calcium carbonate, aluminum hydroxide gel or non-gel aluminum hydroxide was added to a phosphate solution, titrated (HCl or NaOH), shaken and centrifuged to four different pH levels at 37 degrees C (simulating the gastrointestinal milieu). The difference in phosphate concentration between that of the initial and that of the supernatant represented from the bound phosphate in the precipitate. After 4 h at a pH of 6 (representing the intestinal condition after a meal), the binding percentage was: calcium acetate = 95.6%, calcium HMB = 92.6%, calcium carbonate = 46.4%, aluminum hydroxide gel = 33.4% and non-gel aluminum hydroxide = 17.8%. There was no significant difference ($p > 0.05$) between calcium HMB and calcium acetate. These results suggest that calcium HMB is an efficient phosphate binder in vitro, which may predict its effective role in vivo.

CT Acetates: ME, metabolism
Acetates: PD, pharmacology
Aluminum: ME, metabolism
Aluminum: PD, pharmacology

Binding Sites
Calcium: ME, metabolism
Calcium: PD, pharmacology
Calcium Carbonate: ME, metabolism
Calcium Carbonate: PD, pharmacology
Hydrogen-Ion Concentration
Phosphates: ME, metabolism
Time Factors
*Uremia: DT, drug therapy
Uremia: ME, metabolism
Valerates: ME, metabolism
*Valerates: PD, pharmacology

L56 ANSWER 6 OF 6 MEDLINE on STN
ACCESSION NUMBER: 67201184 MEDLINE
DOCUMENT NUMBER: PubMed ID: 4166104
TITLE: Neonatal death associated with isovalericacidaemia.
AUTHOR: Newman C G; Wilson B D; Callaghan P; Young L
SOURCE: Lancet, (1967 Aug 26) 2 (7513) 439-42.
Journal code: 2985213R. ISSN: 0140-6736.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 196709
ENTRY DATE: Entered STN: 19900101
Last Updated on STN: 19980206
Entered Medline: 19670924
CT Check Tags: Male
Acidosis: CO, complications
Acidosis: DT, drug therapy
Bicarbonates: TU, therapeutic use
Chromatography
Chromatography, Gas
*Coenzyme A: ME, metabolism
Electrolytes: TU, therapeutic use
Fatty Acids: BL, blood
Fatty Acids, Nonesterified: AN, analysis
Glucose: TU, therapeutic use
Hemorrhage: CO, complications
Humans
Hypocalcemia: CO, complications
Infant Mortality
Infant, Newborn
*Leucine: ME, metabolism
*Metabolism, Inborn Errors
Metabolism, Inborn Errors: CO, complications
***Valerates: ME, metabolism**

L62 ANSWER 1 OF 2804 MEDLINE on STN
ACCESSION NUMBER: 2006045266 IN-PROCESS
DOCUMENT NUMBER: PubMed ID: 16433798
TITLE: Confluent and reticulate papillomatosis (Gougerot-Carteaud syndrome): a minocycline-responsive dermatosis without evidence for yeast in pathogenesis. A study of 39 patients and a proposal of diagnostic criteria.

AUTHOR: **Davis M D P**; Weenig R H; Camilleri M J
CORPORATE SOURCE: Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, U.S.A.
SOURCE: The British journal of dermatology, (2006 Feb) 154 (2) 287-93.
Journal code: 0004041. ISSN: 0007-0963.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20060126
Last Updated on STN: 20060126

AB Summary Background Confluent and reticulate papillomatosis (CRP) (Gougerot-Carteaud syndrome) is a disorder that has been characterized in only small cohorts of patients. Objectives Better to characterize the clinical and pathological findings of the disorder. Methods We retrospectively reviewed the clinical presentation, response to treatment and histological findings of patients presenting to Mayo Clinic (Rochester, MN, U.S.A.) with CRP. Results The disorder was diagnosed in 39 patients between 1972 and 2003. Mean age at onset of the skin eruption was 15 years (range 8-32); 21 patients (54%) were male; most were white; most (33) presented for reasons of cosmesis; and eight described the rash as mildly pruritic. At presentation, the skin eruption had been present for a mean of 3.1 years (range 3 months-20 years) and had been recalcitrant to treatment, including antifungal treatment. Typical objective findings were scaling brown macules and patches and velvety papules and plaques, reticulated and papillomatous at least in part, involving the upper trunk, axillae and neck. The most frequent initial diagnostic impressions were tinea versicolor, acanthosis nigricans and CRP. Scales in 32 cases were examined with potassium hydroxide: eight (25%) showed hyphae, and 24 (75%) did not. Skin biopsy specimens from 21 patients showed variable degrees of hyperkeratosis, acanthosis and papillomatosis. Minocycline was prescribed for 22 patients, of whom 14 of 18 (78%) had complete clearing of the skin eruption and four (22%) a partial response. The skin eruptions recurred after stopping treatment in six patients. Conclusions CRP occurs predominantly in young adults and teenagers, with cosmetically displeasing brown scaling patches and plaques affecting the neck, upper trunk and axillae. Frequently, the diagnosis is delayed and the disorder not recognized by physicians, including dermatologists. Clinically, the eruption is most often confused with tinea versicolor. Potassium hydroxide staining of the scale is negative in the majority of cases, implying that fungi are not involved in the pathogenesis of this condition, as has been previously proposed. It is important to recognize this disorder, because minocycline therapy is highly effective in most patients. Criteria for the diagnosis are proposed.

=>